

EULAR evidence based recommendations for gout. Part  
force of the EULAR Standing Committee For International  
Therapeutics (ESCISIT)

Annals of the Rheumatic Diseases

65, 1312-1324

DOI: [10.1136/ard.2006.055269](https://doi.org/10.1136/ard.2006.055269)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pathophysiology, Clinical Presentation and Treatment of Gout. <i>Drugs</i> , 2006, 66, 1547-1563.	4.9	46
2	EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1312-1324.	0.5	1,079
3	The changing epidemiology of gout. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 443-449.	3.2	155
4	EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 377-388.	0.5	738
5	Clinical features and risk factors of postsurgical gout. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1271-1275.	0.5	57
6	Why is gout so poorly managed?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1269-1270.	0.5	72
7	Treatment of acute gout-like arthritis in an emergency setting: prednisolone versus indomethacin. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 604-605.	3.2	1
8	Are joints affected by gout also affected by osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1374-1377.	0.5	119
9	Is gout associated with reduced quality of life? A case-control study. <i>Rheumatology</i> , 2007, 46, 1441-1444.	0.9	140
10	Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1311-1315.	0.5	181
11	International survey on the diagnosis and management of gout. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1685-1686.	0.5	29
12	Therapeutic advances in gout. <i>Current Opinion in Rheumatology</i> , 2007, 19, 122-127.	2.0	34
13	Differential Diagnosis of a Patient Presenting With a Knee Effusion. <i>Advanced Emergency Nursing Journal</i> , 2007, 29, 209-227.	0.2	1
14	Imaging modalities and monitoring measures of gout. <i>Current Opinion in Rheumatology</i> , 2007, 19, 128-133.	2.0	49
16	Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. <i>European Journal of Radiology</i> , 2007, 62, 437-443.	1.2	76
17	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1560-1567.	0.5	325
18	Management of Gout in Older Adults. <i>Drugs and Aging</i> , 2007, 24, 21-36.	1.3	27
19	Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. <i>Clinical Pharmacokinetics</i> , 2007, 46, 623-644.	1.6	153

#	ARTICLE	IF	CITATIONS
20	Gota y corticosteroides: luces y sombras. Seminarios De La Fundaci3n Espa3ola De Reumatolog3a, 2007, 8, 200-204.	0.1	0
21	Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?. Arthritis and Rheumatism, 2007, 57, 1324-1328.	6.7	139
22	Diagnostic pratique des Arthropathies microcristallines. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 138-146.	0.0	11
23	La goutte m3dicamenteuse. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 150-152.	0.0	0
27	Traitement de la Goutte. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 160-167.	0.0	15
29	Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events. Seminars in Dialysis, 2007, 20, 391-395.	0.7	133
30	New treatments for gout. Joint Bone Spine, 2007, 74, 313-315.	0.8	6
31	Drug discovery for hyperuricemia. Expert Opinion on Drug Discovery, 2007, 2, 1251-1261.	2.5	18
34	Elderly-onset gout: a review. Rheumatology International, 2007, 28, 1-6.	1.5	40
35	Recent developments in crystal-induced inflammation pathogenesis and management. Current Rheumatology Reports, 2007, 9, 243-250.	2.1	19
36	Int3r3t des orth3ses plantaires dans la gonarthrose et la coxarthrose. 3laboration de recommandations fran3aises pour la pratique clinique. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 1255-1263.	0.0	2
37	Pain management in gout. Current Pain and Headache Reports, 2008, 12, 418-422.	1.3	5
38	Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation. Current Rheumatology Reports, 2008, 10, 218-227.	2.1	171
39	Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Current Rheumatology Reports, 2008, 10, 235-248.	2.1	13
40	Treatment3failure gout: A moving target. Arthritis and Rheumatism, 2008, 58, 2587-2590.	6.7	49
41	Gout management: Let's get it right this time. Arthritis and Rheumatism, 2008, 59, 1535-1537.	6.7	14
42	Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 283week, phase III, randomized, double3blind, parallel3group trial. Arthritis and Rheumatism, 2008, 59, 1540-1548.	6.7	520
43	Int3r3t de lâ3chographie dans le diagnostic des gouttes atypiques. 3 propos de deux observations. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 886-889.	0.0	0

#	ARTICLE	IF	CITATIONS
45	Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. <i>British Journal of Pharmacology</i> , 2008, 153, 1288-1295.	2.7	73
46	Tophi as first clinical sign of gout. <i>International Journal of Dermatology</i> , 2008, 47, 49-51.	0.5	23
47	Dietary manipulation in musculoskeletal conditions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 535-561.	1.4	18
48	Is there an evidence-based efficacy for the use of foot orthotics in knee and hip osteoarthritis? Elaboration of French clinical practice guidelines. <i>Joint Bone Spine</i> , 2008, 75, 714-720.	0.8	29
49	Management of Hyperuricemia and Gout in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 52, 994-1009.	2.1	23
50	A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout. <i>Drug Safety</i> , 2008, 31, 643-665.	1.4	243
51	Drug-Related Deaths. <i>Drug Safety</i> , 2008, 31, 703-713.	1.4	38
52	Overview of the Management of Acute Gout and the Role of Adrenocorticotrophic Hormone. <i>Drugs</i> , 2008, 68, 407-415.	4.9	30
53	Acute Arthritis in the Elderly: Differential Diagnosis and Treatment. <i>International Journal of Gerontology</i> , 2008, 2, 83-90.	0.7	1
54	Developments in the scientific and clinical understanding of gout. <i>Arthritis Research and Therapy</i> , 2008, 10, 221.	1.6	83
56	Understanding deficient elimination of uric acid. <i>Lancet, The</i> , 2008, 372, 1929-1930.	6.3	9
57	Should prednisolone be first-line therapy for acute gout?. <i>Lancet, The</i> , 2008, 372, 1301.	6.3	16
58	Gouty polyarthritis with sacroiliitis: a rare association and insight into newer management and dietary strategies. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 195-198.	0.9	2
59	A fresh look at natural tropolonoids. <i>Natural Product Reports</i> , 2008, 25, 118-138.	5.2	147
60	EULAR recommendations for the management of Behcet disease. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1656-1662.	0.5	624
61	Survey on management of gout among Dutch rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1049-1049.	0.5	11
62	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. <i>Future Rheumatology</i> , 2008, 3, 421-427.	0.2	8
63	First metatarsophalangeal joint aspiration using a 29-gauge needle. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 273-275.	0.5	28

#	ARTICLE	IF	CITATIONS
64	Management of gout. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 81-89.	0.6	9
65	Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 960-966.	0.5	405
66	Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. <i>Rheumatology</i> , 2008, 48, 188-194.	0.9	217
67	Optimizing Therapy With Allopurinol: Factors Limiting Hypouricemic Efficacy. <i>American Journal of the Medical Sciences</i> , 2008, 335, 219-226.	0.4	20
68	We can make gout management more successful now. <i>Current Opinion in Rheumatology</i> , 2008, 20, 167-172.	2.0	43
69	How PCP Education Can Impact Gout Management. <i>Journal of Clinical Rheumatology</i> , 2008, 14, S42-S46.	0.5	12
71	Gout. <i>Journal of Clinical Rheumatology</i> , 2008, 14, S55-S62.	0.5	65
72	Gout. <i>Journal of Clinical Rheumatology</i> , 2008, 14, S47-S54.	0.5	10
73	Chronic tophaceous gout presenting as acute arthritis during an acute illness: a case report. <i>Cases Journal</i> , 2008, 1, 238.	0.4	6
74	Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. <i>Core Evidence</i> , 2010, 4, 25.	4.7	11
75	Gout. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2009, 106, 549-55.	0.6	71
76	Patient risk factors and adverse drug interactions in the treatment of acute gouty arthritis in the elderly: a case report. <i>Cases Journal</i> , 2009, 2, 6602.	0.4	4
77	Febuxostat: a new treatment for hyperuricaemia in gout. <i>Rheumatology</i> , 2009, 48, ii15-ii19.	0.9	72
78	Interleukin-1 blockade: a magic wand for gout?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 594-596.	3.5	4
79	Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter?. <i>Journal of Rheumatology</i> , 2009, 36, 1032-1040.	1.0	79
80	Febuxostat treatment for gout: what the clinician needs to know. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 67-69.	1.2	0
81	EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 8-17.	0.5	324
82	Opportunities for improving medication use and monitoring in gout. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1265-1270.	0.5	87

#	ARTICLE	IF	CITATIONS
83	Introduction. <i>Rheumatology</i> , 2009, 48, ii1-ii1.	0.9	2
84	Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 12-13.	3.2	1
85	Treating to target: a strategy to cure gout. <i>Rheumatology</i> , 2009, 48, ii9-ii14.	0.9	120
86	Gout in the Elderly – A Population Health Study. <i>Journal of Rheumatology</i> , 2009, 36, 822-830.	1.0	34
87	Gout and Quality of Life: Table 1.. <i>Journal of Rheumatology</i> , 2009, 36, 865-868.	1.0	15
88	Recent insights into the pathogenesis of hyperuricaemia and gout. <i>Human Molecular Genetics</i> , 2009, 18, R177-R184.	1.4	103
89	Acute monoarthritis: What is the cause of my patient's painful swollen joint?. <i>Cmaj</i> , 2009, 180, 59-65.	0.9	49
91	Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 3-7.	0.5	89
92	Impact of a Rheumatology Consultation Service on the Diagnostic Accuracy and Management of Gout in Hospitalized Patients. <i>Journal of Rheumatology</i> , 2009, 36, 1699-1704.	1.0	26
93	Colchicine Update: 2008. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 411-419.	1.6	252
95	Gout Study Group: Update on hyperuricemia and gout. <i>Joint Bone Spine</i> , 2009, 76, 444-446.	0.8	26
96	A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. <i>Current Rheumatology Reports</i> , 2009, 11, 135-140.	2.1	109
98	Febuxostat. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 191-192.	21.5	36
99	Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout. <i>Journal of Rheumatology</i> , 2009, 36, 1273-1282.	1.0	233
100	Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 51-56.	0.5	138
101	Management of gout: Primary care approach. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2009, 51, 471-477.	0.2	1
102	Gout – what are the treatment options?. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1319-1328.	0.9	35
104	New insights into the epidemiology of gout. <i>Rheumatology</i> , 2009, 48, ii2-ii8.	0.9	169

#	ARTICLE	IF	CITATIONS
105	Etoricoxib. <i>Drugs</i> , 2009, 69, 1513-1532.	4.9	34
106	Efficacy of intra-articular hyaluronan (Synvisc®) for the treatment of osteoarthritis affecting the first metatarsophalangeal joint of the foot (hallux limitus): study protocol for a randomised placebo controlled trial. <i>Journal of Foot and Ankle Research</i> , 2009, 2, 2.	0.7	18
107	Gout. Novel therapies for treatment of gout and hyperuricemia. <i>Arthritis Research and Therapy</i> , 2009, 11, 236.	1.6	71
108	Adherence with urate-lowering therapies for the treatment of gout. <i>Arthritis Research and Therapy</i> , 2009, 11, R46.	1.6	153
109	What lies behind serum urate concentration? Insights from genetic and genomic studies. <i>Genome Medicine</i> , 2009, 1, 118.	3.6	33
110	The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence. <i>Journal of Human Nutrition and Dietetics</i> , 2009, 22, 3-11.	1.3	32
111	A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 892-897.	0.5	149
113	Severe hip and knee pain in a man with chronic tophaceous gout. <i>International Journal of Rheumatic Diseases</i> , 2009, 12, 57-60.	0.9	2
114	A survey on the management of gout in Malaysia. <i>International Journal of Rheumatic Diseases</i> , 2009, 12, 329-335.	0.9	8
115	Factors Associated With Recurrent Hospital Admissions for Gout. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 271-274.	0.5	34
116	Gout: new advances in the diagnosis and management of an old disease. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 203-220.	0.3	8
117	Update on emerging urate-lowering therapies. <i>Current Opinion in Rheumatology</i> , 2009, 21, 143-149.	2.0	45
118	Reassessing serum urate targets in the management of refractory gout: can you go too low?. <i>Current Opinion in Rheumatology</i> , 2009, 21, 138-142.	2.0	11
119	Update on factors predisposing to gout. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 75-87.	0.3	3
121	A roadmap for education to improve the quality of care in gout. <i>Current Opinion in Rheumatology</i> , 2010, 22, 173-180.	2.0	20
123	Advances and unmet needs in gout. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 187-197.	0.3	0
125	Adherence to treatment guidelines in two primary care populations with gout. <i>Rheumatology International</i> , 2010, 30, 749-753.	1.5	37
126	International position paper on febuxostat. <i>Clinical Rheumatology</i> , 2010, 29, 835-840.	1.0	49

#	ARTICLE	IF	CITATIONS
127	Gout, Hyperuricemia, and Parkinson's Disease: A Protective Effect?. <i>Current Rheumatology Reports</i> , 2010, 12, 149-155.	2.1	19
128	Crystal arthropathies. <i>Medicine</i> , 2010, 38, 146-150.	0.2	3
129	Urate-Lowering Therapy for Gout: Focus on Febuxostat. <i>Pharmacotherapy</i> , 2010, 30, 594-608.	1.2	90
130	Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials. <i>Clinical Therapeutics</i> , 2010, 32, 2386-2397.	1.1	101
131	Epidemiology of gout: An update. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 811-827.	1.4	157
132	Irrelevance of the WHO analgesic ladder for managing rheumatic pain. <i>Joint Bone Spine</i> , 2010, 77, 1-3.	0.8	11
133	High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. <i>Arthritis and Rheumatism</i> , 2010, 62, 1060-1068.	6.7	416
134	Expression and function of CXCL16 in a novel model of gout. <i>Arthritis and Rheumatism</i> , 2010, 62, 2536-2544.	6.7	14
135	Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2010, 62, 3064-3076.	6.7	264
136	Interleukin-1 antagonism in acute gout: Is targeting a single cytokine the answer?. <i>Arthritis and Rheumatism</i> , 2010, 62, 2845-2849.	6.7	27
138	Advances in the proper use of colchicine and adapting dosages in other countries: Comment on the article by Terkeltaub et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 3126-3127.	6.7	4
139	Dietary purines in vegetarian meat analogues. <i>Journal of the Science of Food and Agriculture</i> , 2010, 90, 2352-2357.	1.7	24
141	The current state of care in gout: Addressing the need for better understanding of an ancient disease. <i>Journal of the American Academy of Nurse Practitioners</i> , 2010, 22, 623-636.	1.4	8
142	Update on gout and hyperuricemia. <i>International Journal of Clinical Practice</i> , 2010, 64, 371-377.	0.8	51
143	REVIEW: Management of gout: beyond allopurinol. <i>Internal Medicine Journal</i> , 2010, 40, 545-553.	0.5	7
144	Measurement of Purine Contents in Korean Alcoholic Beverages. <i>The Journal of the Korean Rheumatism Association</i> , 2010, 17, 368.	0.1	3
145	Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 1.	0.8	9
146	Miscellaneous conditions. , 2010, , 337-350.		0



#	ARTICLE	IF	CITATIONS
147	New advances in the treatment of gout: review of pegloticase. Therapeutics and Clinical Risk Management, 2010, Volume 6, 543-550.	0.9	39
148	Management of hyperuricemia in gout: focus on febuxostat. Clinical Interventions in Aging, 2010, 5, 7.	1.3	45
149	Formulary Drug Reviews - Colchicine. Hospital Pharmacy, 2010, 45, 244-252.	0.4	0
150	Diet and complementary therapies. , 2010, , 185-197.		0
151	The modern management of gout. Rheumatology, 2010, 49, 5-14.	0.9	54
152	Management of inflammatory arthritis in older people. Reviews in Clinical Gerontology, 2010, 20, 42-55.	0.5	2
153	Treatment failure gout: failure to treat?. Rheumatology, 2010, 49, 2233-2234.	0.9	7
154	The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology, 2010, 49, 2391-2399.	0.9	88
155	A Diagnostic Rule for Acute Gouty Arthritis in Primary Care Without Joint Fluid Analysis. Archives of Internal Medicine, 2010, 170, 1120-6.	4.3	170
156	Impact of diabetes against the future risk of developing gout. Annals of the Rheumatic Diseases, 2010, 69, 2090-2094.	0.5	83
157	Chronic gout: epidemiology, disease progression, treatment and disease burden. Current Medical Research and Opinion, 2010, 26, 2813-2821.	0.9	90
158	Gout: Nonsteroidal Anti-inflammatory Drugs and Colchicine to Prevent Painful Flares During Early Urate-Lowering Therapy. Journal of Pain and Palliative Care Pharmacotherapy, 2010, 24, 397-401.	0.5	11
159	Nonsteroidal Anti-inflammatory Drugs and Colchicine to Prevent Gout Flare During Early Urate-Lowering Therapy: Perspectives on Alternative Therapies and Costs. Journal of Pain and Palliative Care Pharmacotherapy, 2010, 24, 402-404.	0.5	6
160	Colchicine for the treatment of gout. Expert Opinion on Pharmacotherapy, 2010, 11, 2933-2938.	0.9	37
161	Uric acid and evolution. Rheumatology, 2010, 49, 2010-2015.	0.9	268
162	Hyperuricaemia and gout: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 1738-1743.	0.5	47
163	Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology, 2010, 49, 105-111.	0.9	59
164	Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Annals of the Rheumatic Diseases, 2010, 69, 1097.3-1102.	0.5	55

#	ARTICLE	IF	CITATIONS
165	Patients and providers view gout differently: a qualitative study. <i>Chronic Illness</i> , 2010, 6, 263-271.	0.6	109
166	Diagnosing and Treating Gout: A Review to Aid Primary Care Physicians. <i>Postgraduate Medicine</i> , 2010, 122, 157-161.	0.9	40
167	Incentives for Drug Development â€” The Curious Case of Colchicine. <i>New England Journal of Medicine</i> , 2010, 362, 2045-2047.	13.9	64
169	The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. <i>Arthritis Research and Therapy</i> , 2010, 12, R63.	1.6	420
170	Update on gout: new therapeutic strategies and options. <i>Nature Reviews Rheumatology</i> , 2010, 6, 30-38.	3.5	306
171	Oral Colchicine (Colcrys®). <i>Drugs</i> , 2010, 70, 1603-1613.	4.9	57
172	EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 483-489.	0.5	499
173	The Dynamics of Chronic Gout Treatment: Medication Gaps and Return to Therapy. <i>American Journal of Medicine</i> , 2010, 123, 54-59.	0.6	43
175	Gout. <i>Lancet</i> , The, 2010, 375, 318-328.	6.3	818
176	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
177	Oral Colchicine (Colcrys®) in the Treatment and Prophylaxis of Gout. <i>Drugs and Aging</i> , 2010, 27, 855-857.	1.3	9
178	Febuxostat for the Management of Hyperuricaemia in Patients with Gout. <i>Pharmacoeconomics</i> , 2011, 29, 133-140.	1.7	54
179	Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors. <i>Journal of Rheumatology</i> , 2011, 38, 1385-1389.	1.0	37
180	EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 571-575.	0.5	193
181	European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 563-570.	0.5	418
183	Progress and controversies in treatment. <i>Nature Reviews Rheumatology</i> , 2011, 7, 77-78.	3.5	10
184	The Epidemiology of Uric Acid and Fructose. <i>Seminars in Nephrology</i> , 2011, 31, 410-419.	0.6	127
185	Difficult-to-Treat Gouty Arthritis. <i>Drugs</i> , 2011, 71, 1413-1439.	4.9	43

#	ARTICLE	IF	CITATIONS
186	Gout. <i>New England Journal of Medicine</i> , 2011, 364, 443-452.	13.9	435
187	All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d1165-d1165.	2.4	553
188	The Challenges of Gout Management in the Elderly. <i>Drugs and Aging</i> , 2011, 28, 591-603.	1.3	34
189	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 896-904.	0.5	831
190	Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. <i>Arthritis Research and Therapy</i> , 2011, 13, R53.	1.6	105
191	Contemporary epidemiology of gout in the UK general population. <i>Arthritis Research and Therapy</i> , 2011, 13, R39.	1.6	113
193	Management of Gout in the Older Adult. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 271-285.	3.0	26
198	Physiopathologie et traitement de l'œ™inflammation goutteuse. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, S122-S128.	0.0	2
199	Goutte et pathologies cardiovasculaires. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, S129-S133.	0.0	2
202	Pain and ketoprofen: what is its role in clinical practice?. <i>Reumatismo</i> , 2011, 62, 172-88.	0.4	29
203	Gout: Current Insights and Future Perspectives. <i>Journal of Pain</i> , 2011, 12, 1113-1129.	0.7	40
204	Antiinflamatorios no esteroideos: farmacodinãmica, reacciones adversas e indicaciones en reumatologÃa. <i>Medicine</i> , 2011, 10, 6255-6261.	0.0	0
205	Gout therapeutics: new drugs for an old disease. <i>Lancet, The</i> , 2011, 377, 165-177.	6.3	202
207	Clinical applications of drug desensitization in the Asia-Pacific region. <i>Asia Pacific Allergy</i> , 2011, 1, 2-11.	0.6	13
208	The epidemiology and treatment of gout. <i>Open Access Rheumatology: Research and Reviews</i> , 2011, 3, 73.	0.8	10
209	Renal Function in Gout. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 7-13.	0.5	105
210	Colchicine-Induced Rhabdomyolysis in a Heart/Lung Transplant Patient With Concurrent Use of Cyclosporin, Pravastatin, and Azithromycin. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 28-30.	0.5	32
211	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355.	0.5	41

#	ARTICLE	IF	CITATIONS
212	Impact of Deficits in Gout Care on Hospitalizations. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 389-391.	0.5	9
213	A New Standard of Care? Studies on Febuxostat in the Management of Hyperuricemia With and Without Gout. <i>Journal of Clinical Rheumatology</i> , 2011, 17, S11-S12.	0.5	0
214	Development and Evaluation of a Survey of Gout Patients Concerning Their Knowledge About Gout. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 242-248.	0.5	28
215	When Common Diagnosis Is Not Common Enough.... <i>Internal Medicine</i> , 2011, 50, 3045-3046.	0.3	0
216	Synovial fluid analysis for crystals. <i>Current Opinion in Rheumatology</i> , 2011, 23, 161-169.	2.0	62
217	Acute gout management during hospitalization: a need for a protocol. <i>Internal Medicine Journal</i> , 2011, 41, 610-617.	0.5	25
218	Pegloticase. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 17-18.	21.5	81
219	Serum Urate as a Soluble Biomarker in Chronic Goutâ€”Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 483-500.	1.6	45
220	The Independent Impact of Congestive Heart Failure Status and Diuretic Use on Serum Uric Acid Among Men with a High Cardiovascular Risk Profile: A Prospective Longitudinal Study. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 471-476.	1.6	20
221	Treatment adherence in patients with gout. <i>Joint Bone Spine</i> , 2011, 78, 456-459.	0.8	73
222	Glucocorticoids. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 891-900.	1.4	65
223	Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 392-398.	2.3	48
224	Febuxostat for treatment of chronic gout. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 389-398.	0.5	32
225	Prevalence of hyperuricemia in Bangkok population. <i>Clinical Rheumatology</i> , 2011, 30, 887-893.	1.0	72
226	No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. <i>Diabetologia</i> , 2011, 54, 2561-2569.	2.9	89
227	Orthopaedic Case of the Month: Medial Knee Pain in a 69-year-old Man. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 312-316.	0.7	2
228	Gouty arthritis: Understanding the disease state and management options in primary care. <i>Advances in Therapy</i> , 2011, 28, 748-760.	1.3	8
229	Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?. <i>Current Rheumatology Reports</i> , 2011, 13, 154-159.	2.1	43

#	ARTICLE	IF	CITATIONS
230	Chronic kidney disease in gout in a managed care setting. <i>BMC Nephrology</i> , 2011, 12, 36.	0.8	37
231	Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. <i>Arthritis Care and Research</i> , 2011, 63, 1605-1612.	1.5	97
232	Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. <i>Arthritis and Rheumatism</i> , 2011, 63, 412-421.	6.7	199
233	Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. <i>Arthritis and Rheumatism</i> , 2011, 63, 3136-3141.	6.7	1,385
234	A two-stage approach to the treatment of hyperuricemia in gout: The "dirty dish" hypothesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 4002-4006.	6.7	67
236	HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3567-3572.	0.4	126
237	Managing Your Patient with Gout: A Review of Treatment Options. <i>Postgraduate Medicine</i> , 2011, 123, 56-71.	0.9	12
238	2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia. <i>Physician and Sportsmedicine</i> , 2011, 39, 98-123.	1.0	44
239	New and emerging therapies for gout. <i>Clinical Investigation</i> , 2011, 1, 1563-1575.	0.0	1
240	Treatment and Prophylaxis of Gout Flare in the Clinic: An Office-Based Approach to Gout Management. <i>Postgraduate Medicine</i> , 2011, 123, 151-165.	0.9	3
241	Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 597-604.	0.5	81
242	Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011, 30, 1018-1029.	0.4	244
243	Febuxostat for the treatment of hyperuricemia in patients with gout. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 485-493.	0.3	3
244	Efficacy and safety of febuxostat in patients with hyperuricemia and gout. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 245-253.	1.2	30
245	Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 711.	3.8	433
246	Frequency and risk factors of gout flares in a large population-based cohort of incident gout. <i>Rheumatology</i> , 2011, 50, 973-981.	0.9	98
247	Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1264-1271.	0.5	187
249	Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. <i>Current Medical Research and Opinion</i> , 2011, 27, 737-744.	0.9	17

#	ARTICLE	IF	CITATIONS
250	Allopurinol pharmacogenetics: assessment of potential clinical usefulness. <i>Pharmacogenomics</i> , 2011, 12, 1741-1749.	0.6	35
251	Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma. <i>Case Reports in Medicine</i> , 2011, 2011, 1-3.	0.3	9
252	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. <i>Rheumatology</i> , 2011, 50, 740-745.	0.9	79
253	Gout as a cause of posterior ankle pain. <i>International Musculoskeletal Medicine</i> , 2011, 33, 120-122.	0.1	1
254	Hyperuricemia and Gout: New Concepts in Diagnosis and Management. <i>Postgraduate Medicine</i> , 2012, 124, 98-109.	0.9	37
255	Genetics of Gout. , 2012, , 85-93.		1
256	Diagnosis of Gout. , 2012, , 94-104.		0
257	Up-to-date management of gout. <i>Current Opinion in Rheumatology</i> , 2012, 24, 145-151.	2.0	12
258	Recent advances in management of gout. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 407-417.	0.2	54
259	Debulking the Urate Load to Feel Better. <i>Journal of Rheumatology</i> , 2012, 39, 1311-1313.	1.0	6
260	A new 'package of care' strategy for effective gout management. <i>Nature Reviews Rheumatology</i> , 2012, 8, 507-508.	3.5	2
261	Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1839-1848.	0.5	289
262	Latest evidence on gout management: what the clinician needs to know. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 271-286.	1.1	65
263	The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 821-829.	0.7	21
264	Canakinumab in gout. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1265-1275.	1.4	19
265	Patient and provider barriers to effective management of gout in general practice: a qualitative study: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1490-1495.	0.5	173
266	Gout: why is this curable disease so seldom cured?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1765-1770.	0.5	228
267	Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 157-158.	0.5	163

#	ARTICLE	IF	CITATIONS
268	Axial Gout: Cinderella of Gouty Arthropathy!. <i>Journal of Rheumatology</i> , 2012, 39, 1314-1316.	1.0	5
269	Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. <i>Rheumatology</i> , 2012, 51, 1670-1676.	0.9	38
270	Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. <i>Evidence-Based Medicine</i> , 2012, 17, 105-108.	0.6	11
273	Pegloticase: a new biologic for treating advanced gout. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 143-154.	0.3	2
274	Emerging therapies for gout. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 511-518.	1.0	7
275	Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 155-165.	1.6	25
276	Management of Gout. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2133.	3.8	10
277	Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial. <i>American Journal of Medicine</i> , 2012, 125, 1126-1134.e7.	0.6	110
278	Cherry consumption and decreased risk of recurrent gout attacks. <i>Arthritis and Rheumatism</i> , 2012, 64, 4004-4011.	6.7	135
279	Adherence to uric acid treatment guidelines in a rheumatology clinic. <i>Clinical Rheumatology</i> , 2012, 31, 1707-1711.	1.0	11
280	Soluble C-X-C chemokine ligand 16 levels are increased in gout patients. <i>Clinical Biochemistry</i> , 2012, 45, 1368-1373.	0.8	11
281	GOSPEL: Prospective survey of gout in France. Part I: Design and patient characteristics (n=1003). <i>Joint Bone Spine</i> , 2012, 79, 464-470.	0.8	52
282	Usefulness of ultrasonography for gout. <i>Joint Bone Spine</i> , 2012, 79, 441-445.	0.8	70
284	Medical Management of Acute Gout. <i>Journal of Hand Surgery</i> , 2012, 37, 2160-2164.	0.7	1
286	Ácido Úrico como factor de riesgo cardiovascular. <i>Hipertension Y Riesgo Vascular</i> , 2012, 29, 36-43.	0.3	0
287	Acute Gout. <i>Hospital Medicine Clinics</i> , 2012, 1, e87-e96.	0.2	3
288	Una encuesta sobre la evaluación y el tratamiento actual de la gota en Buenos Aires, Argentina. <i>Reumatología Clínica</i> , 2012, 8, 306-309.	0.2	5
289	Febuxostat per il trattamento dell'iperuricemia in pazienti affetti da gotta. <i>Pharmacoeconomics Italian Research Articles</i> , 2012, 14, 47-54.	0.2	0

#	ARTICLE	IF	CITATIONS
290	Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2012, 39, 1859-1866.	1.0	44
291	Achieving treat to target in gout: a clinical practice improvement project. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 450-457.	0.6	27
292	Treat gout with anti-inflammatories and urate-lowering therapies, unless such treatment is ineffective or inappropriate. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 15-18.	0.3	0
293	Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 1-6.	1.0	9
294	Purine-rich foods intake and recurrent gout attacks. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1448-1453.	0.5	147
296	Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 470-472.	0.5	58
297	Perspectives des uricases dans la goutte. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 17-22.	0.0	4
298	Hypouricemic effects of novel concentrative nucleoside transporter 2 inhibitors through suppressing intestinal absorption of purine nucleosides. <i>European Journal of Pharmacology</i> , 2012, 690, 183-191.	1.7	13
299	Gout as autoinflammatory disease: New mechanisms for more appropriated treatment targets. <i>Autoimmunity Reviews</i> , 2012, 12, 66-71.	2.5	68
300	Riloncept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. <i>Arthritis Care and Research</i> , 2012, 64, 1462-1470.	1.5	94
301	The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. <i>BMC Geriatrics</i> , 2012, 12, 11.	1.1	33
302	Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 174.	0.8	32
303	Patients' knowledge and beliefs concerning gout and its treatment: a population based study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 180.	0.8	71
304	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 117.	1.0	152
305	The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 499-506.	0.9	49
306	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1447-1461.	1.5	598
307	Febuxostat for treating chronic gout. <i>The Cochrane Library</i> , 2012, 11, CD008653.	1.5	29
309	Gouty Arthritis Is Not Everything. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2012, 8, 46-47.	0.2	0



#	ARTICLE	IF	CITATIONS
310	A Survey on the Current Evaluation and Treatment of Gout in Buenos Aires, Argentina. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 306-309.	0.2	2
311	Goutte et observation des stratégies de prise en charge en médecine ambulatoire (GOSPEL). Première Étude prospective de la goutte en France. Méthodologie et caractéristiques des patients (n=1003) (Partie I). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 405-411.	0.0	3
313	Challenges Associated with the Management of Gouty Arthritis in Patients with Chronic Kidney Disease: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 166-178.	1.6	45
315	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , 2012, 64, 1431-1446.	1.5	1,268
316	Evaluation and Treatment of Gout as a Chronic Disease. <i>Advances in Therapy</i> , 2012, 29, 935-946.	1.3	21
317	Safety of Urate-Lowering Therapies. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 663-680.	0.8	16
318	Xanthine Oxidase Inhibitor Treatment of Hyperuricemia. , 2012, , 154-173.		2
319	Prophylaxis of Attacks of Acute Gouty Arthritis. , 2012, , 187-193.		1
320	Uric Acid and Renal Function. , 2012, , .		2
321	Clinical features of gout. <i>Reumatismo</i> , 2012, 63, 238-45.	0.4	40
322	Successful use of allopurinol in a patient on dialysis. <i>BMJ Case Reports</i> , 2012, 2012, bcr0220125814-bcr0220125814.	0.2	7
323	Critical appraisal of the role of pegloticase in the management of gout. <i>Open Access Rheumatology: Research and Reviews</i> , 2012, Volume 4, 63-70.	0.8	8
324	Treatment of Acute Gout. , 2012, , 121-130.		0
325	Overview of Gout Therapy Strategy and Targets, and the Management of Refractory Disease. , 2012, , 194-208.		4
327	Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. <i>Arthritis and Rheumatism</i> , 2012, 64, 2529-2536.	6.7	230
328	The Patient's Experience of Gout: New Insights to Optimize Management. <i>Current Rheumatology Reports</i> , 2012, 14, 173-178.	2.1	20
329	Association Between Gout and All-Cause as well as Cardiovascular Mortality: A Systematic Review. <i>Current Rheumatology Reports</i> , 2012, 14, 195-203.	2.1	78
333	Therapeutic perspectives on uricases for gout. <i>Joint Bone Spine</i> , 2012, 79, 237-242.	0.8	48

#	ARTICLE	IF	CITATIONS
334	Improved management of acute gout during hospitalization following introduction of a protocol. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 512-520.	0.9	12
335	The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 327-335.	1.1	10
336	African American patients with gout: efficacy and safety of febuxostat vs allopurinol. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 15.	0.8	22
337	Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. <i>Arthritis and Rheumatism</i> , 2012, 64, 327-338.	6.7	58
338	An update on the pathology and clinical management of gouty arthritis. <i>Clinical Rheumatology</i> , 2012, 31, 13-21.	1.0	42
339	Riloncept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. <i>Arthritis Research and Therapy</i> , 2013, 15, R25.	1.6	103
340	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1411-1421.	0.8	26
341	Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares. <i>BioDrugs</i> , 2013, 27, 401-406.	2.2	13
342	How to manage patients with gout. <i>Current Medical Research and Opinion</i> , 2013, 29, 17-24.	0.9	4
343	Cost-effectiveness of febuxostat in chronic gout. <i>European Journal of Health Economics</i> , 2013, 15, 453-63.	1.4	35
344	Dual-Energy Computed Tomography for Gout Diagnosis and Management. <i>Current Rheumatology Reports</i> , 2013, 15, 301.	2.1	49
345	A qualitative and quantitative analysis of the characteristics of gout patient education resources. <i>Clinical Rheumatology</i> , 2013, 32, 771-778.	1.0	30
346	Chinese herbal medicine for gout: a systematic review of randomized clinical trials. <i>Clinical Rheumatology</i> , 2013, 32, 943-959.	1.0	29
347	Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China. <i>Clinical Rheumatology</i> , 2013, 32, 1633-1640.	1.0	14
348	Diabetes and gout: efficacy and safety of febuxostat and allopurinol. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 1049-1055.	2.2	27
349	Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. <i>Arthritis Care and Research</i> , 2013, 65, 2008-2014.	1.5	24
350	Gout: a critical analysis of scientific development. <i>Rheumatology International</i> , 2013, 33, 2743-2750.	1.5	20
353	Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature. <i>Joint Bone Spine</i> , 2013, 80, 178-182.	0.8	63

#	ARTICLE	IF	CITATIONS
354	Imaging in rheumatology: reconciling radiology and rheumatology. <i>Insights Into Imaging</i> , 2013, 4, 799-810.	1.6	27
355	The role of Western herbal medicine in the treatment of gout. <i>Journal of Herbal Medicine</i> , 2013, 3, 157-170.	1.0	15
356	Safety and Efficacy of Allopurinol in Chronic Kidney Disease. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1507-1516.	0.9	30
357	'Golden Kernels within the skin': disseminated cutaneous gout. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009735-bcr2013009735.	0.2	11
359	Utility of ultrasound in the diagnosis of chronic worsened gout. <i>Journal of Medical Ultrasonics (2001)</i> , 2013, 40, 467-469.	0.6	2
360	Chronic gout in the elderly. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 129-137.	1.4	20
362	Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. <i>BMC Family Practice</i> , 2013, 14, 170.	2.9	66
363	Reversal of chronic refractory tophaceous gout with erosions with pegloticase. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 369-370.	0.9	1
365	Gout. <i>BMJ, The</i> , 2013, 347, f5648-f5648.	3.0	60
368	New Therapies for Gout. <i>Annual Review of Medicine</i> , 2013, 64, 325-337.	5.0	53
369	Uso de recursos e impacto econ3mico de los pacientes con gota: estudio multic3ntrico de 3mbito poblacional. <i>Reumatolog3a Cl3nica</i> , 2013, 9, 94-100.	0.2	21
371	Polyarticular sonographic assessment of gout: A hospital-based cross-sectional study. <i>Joint Bone Spine</i> , 2013, 80, 295-300.	0.8	29
373	Resolution of Massive Tophaceous Gout with Three Urate-lowering Drugs. <i>American Journal of Medicine</i> , 2013, 126, e9-e10.	0.6	14
374	ACTH as first line treatment for acute gout in 181 hospitalized patients. <i>Joint Bone Spine</i> , 2013, 80, 291-294.	0.8	33
376	Eficacia y efectividad de los tratamientos reductores de la uricemia. <i>Seminarios De La Fundaci3n Espaola De Reumatolog3a</i> , 2013, 14, 8-13.	0.1	0
377	Resource Use and Economic Impact of Patients With Gout: A Multicenter, Population-Wide Study. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2013, 9, 94-100.	0.2	9
380	3valuation 3chographique polyarticulaire de la goutte: une 3tude crois3e hospitali3re. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 387-392.	0.0	0
381	New ACR guidelines for gout management hold some surprises. <i>Nature Reviews Rheumatology</i> , 2013, 9, 9-11.	3.5	12

#	ARTICLE	IF	CITATIONS
382	Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2013, 35, 180-189.	1.1	49
383	Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 155-160.	0.3	1
384	Novel drug discovery strategies for gout. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 183-189.	2.5	5
385	Serum uric acid and gout: from the past to molecular biology. <i>Current Medical Research and Opinion</i> , 2013, 29, 3-8.	0.9	64
386	Understanding the doseâ€“response relationship of allopurinol: predicting the optimal dosage. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 932-938.	1.1	33
387	New insights into an old disease: advanced imaging in the diagnosis and management of gout. <i>Postgraduate Medical Journal</i> , 2013, 89, 87-93.	0.9	39
388	Gouty arthritis: an approach for general practice. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013, 55, 307-312.	0.2	3
389	Gout: from international guidelines to current practice. Results from a physician questionnaire. <i>Clinical Rheumatology</i> , 2013, 32, 1693-1694.	1.0	7
390	Long-term safety of pegloticase in chronic gout refractory to conventional treatment. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1469-1474.	0.5	83
391	Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. <i>Rheumatology</i> , 2013, 52, 1623-1629.	0.9	65
392	Epidemiology of gout and hyperuricaemia in Italy during the years 2005â€“2009: a nationwide population-based study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 694-700.	0.5	231
393	Clinically Insignificant Effect of Supplemental Vitamin C on Serum Urate in Patients With Gout: A Pilot Randomized Controlled Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1636-1642.	6.7	68
394	Riloncept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. <i>Rheumatology</i> , 2013, 52, 1285-1292.	0.9	84
395	Treatment of hyperuricaemia and gout. <i>Clinical Medicine</i> , 2013, 13, 400-403.	0.8	14
396	Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 19-29.	0.5	105
397	An Audit of a Therapeutic Drug Monitoring Service for Allopurinol Therapy. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 863-866.	1.0	0
398	New developments in gout. <i>Current Opinion in Rheumatology</i> , 2013, 25, 304-309.	2.0	28
399	Criteria for Gout Diagnosis?. <i>Journal of Rheumatology</i> , 2013, 40, 356-358.	1.0	12

#	ARTICLE	IF	CITATIONS
401	A Delphi Exercise to Identify Characteristic Features of Gout " Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. <i>Journal of Rheumatology</i> , 2013, 40, 498-505.	1.0	25
402	Managing gout needs more than drugs: " Il faut le savoir-faire, l'Art et la mani"re </i>. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 791-793.	0.5	18
403	Imaging Appearances in Gout. <i>Arthritis</i> , 2013, 2013, 1-10.	2.0	53
404	The Colchicine Debacle. <i>JAMA Internal Medicine</i> , 2013, 173, 184.	2.6	4
405	Current Concepts in the Treatment of Gouty Arthritis. <i>Orthopaedic Surgery</i> , 2013, 5, 6-12.	0.7	19
406	Intra-articular glucocorticoids for acute gout. <i>The Cochrane Library</i> , 2013, , CD009920.	1.5	16
407	Hyperuricaemia and gout in <sc>N</sc>ew <sc>Z</sc>ealand rural and urban <sc>M</sc>ori and non- <sc>M</sc>ori communities. <i>Internal Medicine Journal</i> , 2013, 43, 678-684.	0.5	25
408	Role of Interleukin-1 Inhibitors in the Management of Gout. <i>Pharmacotherapy</i> , 2013, 33, 744-753.	1.2	22
409	Ultrasound Learning Curve in Gout: A Disease-Oriented Training Program. <i>Arthritis Care and Research</i> , 2013, 65, 1265-1274.	1.5	19
410	Advice from Professional Societies: Appropriate Use of NSAIDs. <i>Pain Medicine</i> , 2013, 14, S3-S10.	0.9	13
411	Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 826-830.	0.5	232
412	Multinational gout guidelines: how do we move beyond 'd'vu'. <i>Nature Reviews Rheumatology</i> , 2013, 9, 567-569.	3.5	0
413	Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population. <i>Journal of Rheumatology</i> , 2013, 40, 872-876.	1.0	54
414	Gout treatment: should we aim for rapid crystal dissolution?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 635-637.	0.5	22
416	Investigating gout: taking a new approach to an old disease. <i>Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals</i> , 2013, 5, 248-257.	0.0	0
417	Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Research and Therapy</i> , 2013, 15, R123.	1.6	103
418	Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. <i>Arthritis Research and Therapy</i> , 2013, 15, R137.	1.6	82
419	Italian Society of Rheumatology recommendations for the management of gout. <i>Reumatismo</i> , 2013, 65, 4-21.	0.4	29

#	ARTICLE	IF	CITATIONS
420	Editorial paper Gout – new diagnostic and therapeutic options. <i>Reumatologia</i> , 2013, 1, 1-8.	0.5	1
422	Benefit Restrictions and Gout Treatment. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 773-782.	2.2	4
423	Treatment of gout in patients after organ transplantation. <i>Reumatologia</i> , 2013, 3, 215-220.	0.5	1
424	Demographic and Clinical Profile of Nursing Facility Residents with Gout. <i>The Consultant Pharmacist</i> , 2013, 28, 370-382.	0.4	2
425	Association between Vitamin D Insufficiency and Elevated Serum Uric Acid among Middle-Aged and Elderly Chinese Han Women. <i>PLoS ONE</i> , 2013, 8, e61159.	1.1	40
426	Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk. <i>Current Pharmaceutical Design</i> , 2013, 19, 2432-2438.	0.9	154
427	Affections microcristallines. , 2013, , 23-95.		0
428	Managing gout: not a trivial matter. <i>Practice Nursing</i> , 2013, 24, 179-185.	0.1	0
430	Korean Guidelines for Tailored Management of Gout. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 280.	0.4	3
431	A Case of High dose Colchicine with No Efficacy in a Patient with Chronic Kidney Disease Taking Rifampicin. <i>Journal of Rheumatic Diseases</i> , 2014, 21, 314.	0.4	2
432	Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. <i>Drug Design, Development and Therapy</i> , 2014, 8, 245.	2.0	21
433	Efficacy and safety of febuxostat in elderly female patients. <i>Clinical Interventions in Aging</i> , 2014, 9, 1489.	1.3	7
434	Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population. <i>PLoS ONE</i> , 2014, 9, e94294.	1.1	88
435	Apolipoprotein E Gene Polymorphisms Are Associated with Primary Hyperuricemia in a Chinese Population. <i>PLoS ONE</i> , 2014, 9, e110864.	1.1	10
436	Hyperthyroid and Hypothyroid Status Was Strongly Associated with Gout and Weakly Associated with Hyperuricaemia. <i>PLoS ONE</i> , 2014, 9, e114579.	1.1	23
437	Association of Uric Acid with Metabolic Syndrome in Men, Premenopausal Women and Postmenopausal Women. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 2899-2910.	1.2	40
438	SAT0519 – Facilitators and Barriers to Adherence to Urate-Lowering Therapy in African-Americans with Gout: A Qualitative Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 779.3-779.	0.5	0
439	Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia. <i>SpringerPlus</i> , 2014, 3, 592.	1.2	20

#	ARTICLE	IF	CITATIONS
440	Colchicine for acute gout. The Cochrane Library, 2014, , CD006190.	1.5	77
441	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 55-62.	2.2	7
442	Gout treatment: when a tablet is not enough. Nature Reviews Rheumatology, 2014, 10, 193-193.	3.5	4
443	Treatment of Hyperuricemia in Gout. , 2014, , 41-52.		0
444	The Emerging Role of Biotechnological Drugs in the Treatment of Gout. BioMed Research International, 2014, 2014, 1-9.	0.9	13
445	Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open, 2014, 4, e003627.	0.8	46
446	Rapid crystal dissolution in gout: is it feasible and advisable?. International Journal of Clinical Rheumatology, 2014, 9, 395-401.	0.3	2
447	Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout. Annals of Internal Medicine, 2014, 161, 617.	2.0	50
448	Medication Adherence in Gout: A Systematic Review. Arthritis Care and Research, 2014, 66, 1551-1559.	1.5	148
449	Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 2014, 4, e005354-e005354.	0.8	81
450	Imaging in gout: A review of the recent developments. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 131-143.	1.2	49
451	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2014, , CD010120.	1.5	40
452	Uricosuric medications for chronic gout. The Cochrane Library, 2014, , CD010457.	1.5	33
453	Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. International Journal of Clinical Practice, 2014, 68, 633-638.	0.8	20
454	Pharmacokinetics considerations for gout treatments. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 949-957.	1.5	13
455	Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology, 2014, 53, 1920-1926.	0.9	44
456	Eligibility for and Prescription of Urate-Lowering Treatment in Patients With Incident Gout in England. JAMA - Journal of the American Medical Association, 2014, 312, 2684.	3.8	64
459	Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat. Postgraduate Medicine, 2014, 126, 65-75.	0.9	20

#	ARTICLE	IF	CITATIONS
460	Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 318.	0.8	27
461	The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. <i>Arthritis Research and Therapy</i> , 2014, 16, R132.	1.6	57
462	Comparison of two plasma urate assays in patients receiving vitamin C supplementation. <i>Pathology</i> , 2014, 46, 333-335.	0.3	2
463	Diagnosis and Management of Gout in Total Knee Arthroplasty. <i>Orthopaedic Nursing</i> , 2014, 33, 37-40.	0.2	14
464	An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout. <i>Current Opinion in Rheumatology</i> , 2014, 26, 152-161.	2.0	22
465	Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-6.	0.9	15
466	Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. <i>Rheumatology</i> , 2014, 53, 1958-1965.	0.9	35
467	Definition of hyperuricemia and gouty conditions. <i>Current Opinion in Rheumatology</i> , 2014, 26, 186-191.	2.0	336
468	Management of Gouty Arthritis in Patients With Chronic Kidney Disease. <i>American Journal of Therapeutics</i> , 2014, 21, 523-534.	0.5	16
469	Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 400-407.	0.9	28
470	The effect of bariatric surgery on gout: a comparative study. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 1161-1165.	1.0	51
472	Goutte rachidienne: cinq cas, dont deux atteints de la goutte. <i>Revue Du Rhumatisme (Edition) Tj</i> ETQq1 1,0,784314,rgBT /Ome	0.0	0
473	As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. <i>Rheumatology International</i> , 2014, 34, 101-109.	1.5	60
474	Crystal arthropathies. <i>Medicine</i> , 2014, 42, 208-212.	0.2	0
475	Alcohol Quantity and Type on Risk of Recurrent Gout Attacks: An Internet-based Case-crossover Study. <i>American Journal of Medicine</i> , 2014, 127, 311-318.	0.6	101
476	Treatment of acute gout: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 31-38.	1.6	73
478	Long-Term Management of Gout. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 357-374.	0.8	18
479	Treatment of Acute Gout. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 329-341.	0.8	19



#	ARTICLE	IF	CITATIONS
480	Emerging Therapies for Gout. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 375-387.	0.8	36
481	Evaluating Appropriate Use of Prophylactic Colchicine for Gout Flare Prevention. <i>Arthritis Care and Research</i> , 2014, 66, 1258-1262.	1.5	4
482	Allopurinol for chronic gout. <i>The Cochrane Library</i> , 2014, 2014, CD006077.	1.5	48
483	The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors. <i>Journal of rheumatology Supplement, The</i> , 2014, 92, 15-25.	2.2	29
484	Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 177-182.	0.5	170
485	Diagnostic Value of Clinical, Laboratory, and Imaging Findings in Patients with a Clinical Suspicion of Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement, The</i> , 2014, 92, 3-8.	2.2	16
486	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.5	222
487	Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1522-1528.	0.5	155
488	Preventing Attacks of Acute Gout When Introducing Urate-Lowering Therapy: A Systematic Literature Review. <i>Journal of rheumatology Supplement, The</i> , 2014, 92, 42-47.	2.2	14
489	Échographie dans la goutte: un outil utile dans le suivi du traitement hypouricémiant. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 491-494.	0.0	0
490	Febuxostat: drug review and update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 747-758.	1.5	31
492	Efficacy and Safety of a Urate Lowering Regimen in Primary Gout. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 174-180.	0.4	8
493	Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. <i>Arthritis Research and Therapy</i> , 2014, 16, R82.	1.6	60
494	Optimizing current treatment of gout. <i>Nature Reviews Rheumatology</i> , 2014, 10, 271-283.	3.5	158
495	Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. <i>Rheumatology</i> , 2014, 53, 2167-2174.	0.9	92
496	Gout in French Polynesia: A survey of common practices. <i>Joint Bone Spine</i> , 2014, 81, 374-375.	0.8	6
497	Therapeutic Approaches to Chronic Hyperuricemia and Gout. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 243-250.	1.0	22
498	Systematic Review of the Value of Ultrasound and Magnetic Resonance Musculoskeletal Imaging in the Evaluation of Response to Treatment of Gout. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 160-163.	0.2	6

#	ARTICLE	IF	CITATIONS
499	Up-titration of allopurinol in patients with gout. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 25-30.	1.6	42
500	La goutte en Polynésie française: enquête sur la pratique quotidienne. <i>Revue Du Rhumatisme (Edition) Tj ETQ</i> , 2014, 10, 1078-1081.	0.0	0
501	ACTH as a treatment for acute crystal-induced arthritis: Update on clinical evidence and mechanisms of action. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 648-653.	1.6	17
502	Structural Joint Damage in Gout. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 291-309.	0.8	17
503	Revisión sistemática sobre el valor de la ecografía y la resonancia magnética nuclear musculoesqueléticas en la evaluación de la respuesta al tratamiento en la gota. <i>Reumatología Clínica</i> , 2014, 10, 160-163.	0.2	10
504	Le pied métabolique et endocrinien (hors pied diabétique). <i>Revue Du Rhumatisme Monographies</i> , 2014, 81, 183-191.	0.0	0
505	Correction. <i>British Journal of Sports Medicine</i> , 2014, 48, 1396-1396.	3.1	69
506	Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease. <i>Drug Target Insights</i> , 2014, 8, DTI.S16524.	0.9	24
507	Gout: patient education and non-pharmacological treatments. <i>Nursing and Residential Care</i> , 2014, 16, 383-386.	0.1	0
508	Diagnostic Utility of Plain Knee X Ray in Crowned Dens Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1082.1-1082.	0.5	0
509	Adherence to Guidelines and the Screening Tool of Older Persons™ Potentially Inappropriate Prescriptions Criteria for Colchicine Dosing for Gout Treatment in Beneficiaries of the Nova Scotia Seniors™ Pharmacare Program. <i>Clinical Therapeutics</i> , 2015, 37, 2339-2346.	1.1	1
510	The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 495-501.	0.9	54
511	Mapping patients'™ experiences from initial symptoms to gout diagnosis: a qualitative exploration: Table 1. <i>BMJ Open</i> , 2015, 5, e008323.	0.8	30
513	Jicht en pseudojicht. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2015, 31, 355-364.	0.0	0
514	Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 304.	1.6	8
515	Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a cross-sectional observational study. <i>Journal of Foot and Ankle Research</i> , 2015, 8, 41.	0.7	16
516	A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 669-678.	0.9	36
517	Nouvelle approche du traitement de l'hyperuricémie et de la goutte à la lumière des recommandations. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, A23-A26.	0.0	0

#	ARTICLE	IF	CITATIONS
518	Allopurinol adherence among patients with gout: an Italian general practice database study. <i>International Journal of Clinical Practice</i> , 2015, 69, 757-765.	0.8	31
519	Colchicine. <i>American Journal of Therapeutics</i> , 2015, 22, e151-e157.	0.5	29
520	A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 412-415.	0.7	7
521	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 411-418.	0.5	11
522	Cost-Effectiveness Analysis of Allopurinol Versus Febuxostat in Chronic Gout Patients: A U.S. Payer Perspective. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 165-175.	0.5	26
523	Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis. <i>Journal of Rheumatic Diseases</i> , 2015, 22, 356.	0.4	1
524	Association of C-Reactive Protein and Metabolic Disorder in a Chinese Population. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 8228-8242.	1.2	15
525	Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3423.	2.0	46
526	Effects of RuPeng15 Powder (RPP15) on Monosodium Urate Crystal-Induced Gouty Arthritis in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-7.	0.5	9
527	An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. <i>Genetics in Medicine</i> , 2015, 17, 807-814.	1.1	34
528	Ultrasound-Guided Interventional Maneuvers. , 2015, , 339-385.		1
529	How neutrophil extracellular traps orchestrate the local immune response in gout. <i>Journal of Molecular Medicine</i> , 2015, 93, 727-734.	1.7	61
531	A Systematic Review of the Economic and Humanistic Burden of Gout. <i>Pharmacoeconomics</i> , 2015, 33, 1029-1047.	1.7	49
532	Nonsteroidal Anti-inflammatory Drugs for Treatment of Acute Gout. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2276.	3.8	12
533	Is There Evidence to Support Multidisciplinary Healthcare Working in Rheumatology? A Systematic Review of the Literature. <i>Musculoskeletal Care</i> , 2015, 13, 51-66.	0.6	9
534	Évolution du profil des hospitalisations pour goutte dans un service de rhumatologie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 272-273.	0.0	0
535	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 120.	1.6	52
536	Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. <i>BMJ Open</i> , 2015, 5, e007214.	0.8	22

#	ARTICLE	IF	CITATIONS
537	Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 335-343.	0.8	117
538	Gout and the heart: beyond comorbidities. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 329-334.	0.3	0
539	Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1694-1701.	1.0	49
540	Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. <i>Pharmacogenomics</i> , 2015, 16, 1781-1793.	0.6	43
542	Febuxostat for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 395-398.	0.9	9
543	Advances in pharmacotherapy for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 533-546.	0.9	26
544	Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 661-667.	0.5	472
545	Allopurinol use and risk of non-fatal acute myocardial infarction. <i>Heart</i> , 2015, 101, 679-685.	1.2	43
546	Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout. <i>Drugs</i> , 2015, 75, 427-438.	4.9	59
547	Health literacy in patients dealing with gout: a qualitative study. <i>Clinical Rheumatology</i> , 2015, 34, 1599-1603.	1.0	26
548	Gout: Update on Current Therapeutics. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 131-142.	0.6	0
549	Investigational drugs for hyperuricemia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1013-1030.	1.9	44
550	Update on hyperuricaemia and gout with evidence based management guidelines. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2015, 57, 267-272.	0.2	1
551	Why are rheumatologists still reluctant to perform joint-fluid analysis?. <i>Joint Bone Spine</i> , 2015, 82, 139-140.	0.8	4
552	Échographie dans les arthropathies microcristallines. <i>Revue Du Rhumatisme Monographies</i> , 2015, 82, 181-186.	0.0	2
553	Global epidemiology of gout: prevalence, incidence and risk factors. <i>Nature Reviews Rheumatology</i> , 2015, 11, 649-662.	3.5	854
554	The economic burden of gout: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 75-80.	1.6	84
555	Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. <i>Clinical Therapeutics</i> , 2015, 37, 1206-1215.	1.1	17

#	ARTICLE	IF	CITATIONS
556	International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. <i>Rheumatology</i> , 2015, 54, 1797-1805.	0.9	122
557	An open-label, 6-month study of allopurinol safety in gout: The LASSO study. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 174-183.	1.6	82
558	Case study: A case of debilitating gout in the 1st metatarsophalangeal joint. <i>Foot</i> , 2015, 25, 45-50.	0.4	2
559	Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 642-647.	0.5	92
561	Pharmacogenetic considerations in the treatment of gout. <i>Pharmacogenomics</i> , 2015, 16, 619-629.	0.6	5
562	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , 2015, 30, 1633-1638.	1.3	18
565	Identification of patients with gout: elaboration of a questionnaire for epidemiological studies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1684-1690.	0.5	25
566	Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers. <i>AAPS Journal</i> , 2015, 17, 416-426.	2.2	11
567	Hyperuricemia starts at 360 micromoles (6mg/dL). <i>Joint Bone Spine</i> , 2015, 82, 141-143.	0.8	58
568	When gout goes to the heart: does gout equal a cardiovascular disease risk factor?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 631-634.	0.5	35
569	The impact of gout guidelines. <i>Current Opinion in Rheumatology</i> , 2015, 27, 225-230.	2.0	12
570	Current and Emerging Therapies for Gout. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 143-155.	0.6	4
571	New medications in development for the treatment of hyperuricemia of gout. <i>Current Opinion in Rheumatology</i> , 2015, 27, 164-169.	2.0	64
572	Evolution of management of gout. <i>Current Opinion in Rheumatology</i> , 2015, 27, 139-146.	2.0	26
574	Interleukin-1 as a therapeutic target in gout. <i>Current Opinion in Rheumatology</i> , 2015, 27, 156-163.	2.0	48
575	Sonography of the first metatarsophalangeal joint and sonographically guided intraarticular injection of corticosteroid in acute gout attack. <i>Journal of Clinical Ultrasound</i> , 2015, 43, 179-186.	0.4	21
576	Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1933-1942.	2.9	37
577	Impact of allopurinol on risk of myocardial infarction. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 836-842.	0.5	89

#	ARTICLE	IF	CITATIONS
578	First experience with single-source dual-energy computed tomography in six patients with acute arthralgia: a feasibility experiment using joint aspiration as a reference. <i>Skeletal Radiology</i> , 2015, 44, 1573-1577.	1.2	20
579	The management of hyperuricemia with urate deposition. <i>Current Medical Research and Opinion</i> , 2015, 31, 27-32.	0.9	14
580	Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. <i>Scientific Reports</i> , 2014, 4, 5227.	1.6	70
581	Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 341-351.	0.9	43
582	Rules of engagement: turning recommendations into results in the diagnosis and management of gout. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 261-263.	0.9	0
583	Understanding and improving the use of allopurinol in a teaching hospital. <i>Internal Medicine Journal</i> , 2015, 45, 383-390.	0.5	4
584	Molecular mechanisms of pain in crystal-induced arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 98-110.	1.4	23
585	Comparison Between Dual-Energy Computed Tomography and Ultrasound in the Diagnosis of Gout of Various Joints. <i>Academic Radiology</i> , 2015, 22, 1497-1502.	1.3	25
587	Hyperuricaemia with deposition: latest evidence and therapeutic approach. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 225-233.	1.2	19
588	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. <i>Journal of Rheumatology</i> , 2015, 42, 1702-1707.	1.0	79
589	Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy. <i>Clinica Chimica Acta</i> , 2015, 450, 115-120.	0.5	28
590	Evolution of the profile of patients hospitalized for gout in a tertiary rheumatology unit. <i>Joint Bone Spine</i> , 2015, 82, 296-297.	0.8	0
591	A Review of Uric Acid, Crystal Deposition Disease, and Gout. <i>Advances in Therapy</i> , 2015, 32, 31-41.	1.3	184
592	Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 752-756.	0.5	57
593	Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System. <i>Journal of Rheumatology</i> , 2015, 42, 504-512.	1.0	69
594	Management of gout in general practice—a systematic review. <i>Clinical Rheumatology</i> , 2015, 34, 9-16.	1.0	23
596	The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. <i>Rheumatology</i> , 2015, 54, 609-614.	0.9	47
597	A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. , 2016, 20, 15-234.		47

#	ARTICLE	IF	CITATIONS
598	Utility of the Morisky Medication Adherence Scale in gout: a prospective study. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2449-2457.	0.8	25
599	Recent advances in management of gout. <i>Journal of the Korean Medical Association</i> , 2016, 59, 379.	0.1	13
600	Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3509-3517.	2.0	3
601	A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of <i>Terminalia chebula</i> and <i>Terminalia bellerica</i> in subjects with hyperuricemia. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 51.	0.8	3
602	Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3555-3562.	2.0	24
603	Uric Acid and Cardiovascular Disease: An Update. <i>European Cardiology Review</i> , 2016, 11, 54.	0.7	82
604	The Current Situation of Hypertension among Rural Minimal Assurance Family Participants in Liaoning (China): A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 1199.	1.2	2
605	“œt”s complicated”- talking about gout medicines in primary care consultations: a qualitative study. <i>BMC Family Practice</i> , 2016, 17, 114.	2.9	7
606	A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 249.	0.8	12
607	Functional and Structural Characterization of Purine Nucleoside Phosphorylase from <i>Kluyveromyces lactis</i> and Its Potential Applications in Reducing Purine Content in Food. <i>PLoS ONE</i> , 2016, 11, e0164279.	1.1	23
608	Diet and gout “ what is the role of purines?. <i>Nutrition Bulletin</i> , 2016, 41, 155-166.	0.8	7
609	Target Serum Urate: Do Gout Patients Know Their Goal?. <i>Arthritis Care and Research</i> , 2016, 68, 1028-1035.	1.5	18
610	A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial. <i>Clinical Trials</i> , 2016, 13, 665-670.	0.7	5
611	“œYou Don't Have to Be a Drinker to Get Gout, But It Helps” A Content Analysis of the Depiction of Gout in Popular Newspapers. <i>Arthritis Care and Research</i> , 2016, 68, 1721-1725.	1.5	34
612	Predicting allopurinol response in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 277-289.	1.1	46
613	General practitioners' perspectives on the management of gout: a qualitative study. <i>Postgraduate Medical Journal</i> , 2016, 92, 603-607.	0.9	20
614	Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 517-523.	0.4	13
615	Inpatient management of gout in a New Zealand hospital: a retrospective audit. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 205-210.	0.9	11

#	ARTICLE	IF	CITATIONS
616	Impact of the HLA-B58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1373-1381.	0.3	75
617	Tophaceous Gout in the Nasal Root: An Unusual Initial Presentation. <i>American Journal of the Medical Sciences</i> , 2016, 351, 321-322.	0.4	2
618	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
619	The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 69.	0.8	37
620	Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study. <i>Obesity Research and Clinical Practice</i> , 2016, 10, S84-S95.	0.8	29
621	New therapeutic approach to hyperuricemia and gout in the light of recommendations. <i>Joint Bone Spine</i> , 2016, 83, 376-380.	0.8	4
622	Gout, hyperuricemia and chronic kidney disease: New treatment possibilities. <i>Polish Annals of Medicine</i> , 2016, 23, 195-201.	0.3	6
623	Coincidence of monosodium urate monohydrate, calcium pyrophosphate dihydrate, and basic calcium phosphate crystals in the synovial fluid from a single joint. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 167-169.	0.6	0
624	Gout. <i>Lancet</i> , The, 2016, 388, 2039-2052.	6.3	774
625	Urate Handling in the Human Body. <i>Current Rheumatology Reports</i> , 2016, 18, 34.	2.1	106
626	Hyperuricemia and gout: The impact of ultrasonography. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 67-68.	0.1	0
627	Measuring High-Risk Patients' Preferences for Pharmacogenetic Testing to Reduce Severe Adverse Drug Reaction: A Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 767-775.	0.1	24
628	Efficacy of NSAIDs in the Treatment of Rheumatic Diseases. , 2016, , 37-43.		0
629	Détection des cristaux d'urate monosodique dans le liquide synovial après le stockage de longue durée et dans des conditions variables. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 396-397.	0.0	0
630	La ecografía en el diagnóstico de la hiperuricemia asintomática y la gota. <i>Revista Clinica Espanola</i> , 2016, 216, 445-450.	0.2	6
631	Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2016, 3, 53-75.	1.1	5
632	Febuxostat in Hyperuricemic Patients With Advanced CKD. <i>American Journal of Kidney Diseases</i> , 2016, 68, 819-821.	2.1	14
633	Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?. <i>Postgraduate Medicine</i> , 2016, 128, 706-715.	0.9	44



#	ARTICLE	IF	CITATIONS
634	Computational Lexical Analysis of the Language Commonly Used to Describe Gout. <i>Arthritis Care and Research</i> , 2016, 68, 763-768.	1.5	8
635	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
636	Dual-Energy CT for the Musculoskeletal System. <i>Radiology</i> , 2016, 281, 690-707.	3.6	186
637	Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. <i>Advances in Therapy</i> , 2016, 33, 1180-1198.	1.3	14
638	Musculoskeletal ultrasonography in the diagnosis of acute crystalline synovitis. <i>Emergency Radiology</i> , 2016, 23, 623-632.	1.0	1
639	Mobile applications to enhance self-management of gout. <i>International Journal of Medical Informatics</i> , 2016, 94, 67-74.	1.6	33
640	The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. <i>Internal Medicine Journal</i> , 2016, 46, 1075-1080.	0.5	23
641	Ultrasound in the diagnosis of asymptomatic hyperuricemia and gout. <i>Revista Colombiana de Medicina y Salud Pública</i> , 2016, 216, 445-450.	0.3	1
642	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1129-1138.	2.4	13
644	Oral Prednisolone in the Treatment of Acute Gout. <i>Annals of Internal Medicine</i> , 2016, 164, 464.	2.0	57
645	Prevalence of comorbidities and management of gout in a tropical city in Australia. <i>Rheumatology International</i> , 2016, 36, 1753-1758.	1.5	5
647	Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. <i>Arthritis Research and Therapy</i> , 2016, 18, 214.	1.6	100
648	Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. <i>Rheumatology International</i> , 2016, 36, 1747-1752.	1.5	17
649	Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2016, 6, 33082.	1.6	56
650	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. <i>BMJ Open</i> , 2016, 6, e012026.	0.8	5
651	AB0898...Idiopathic Hypertrophic Pachymeningitis: Clinico-Radiological Features and Outcome in Mexican Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1209.2-1209.	0.5	0
652	Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice. <i>Clinical Rheumatology</i> , 2016, 35, 2053-2061.	1.0	25
653	Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 145-159.	1.2	95

#	ARTICLE	IF	CITATIONS
654	The association between gout and radiographic hand, knee and foot osteoarthritis: a cross-sectional study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 169.	0.8	18
655	A cross-sectional internet-based patient survey of the management strategies for gout. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 90.	3.7	18
656	Chronic hyperglycemia may attenuate the serum-uric-acid-lowering effect of low-dose febuxostat in Japanese patients with type 2 diabetes mellitus. <i>Diabetology International</i> , 2016, 7, 308-313.	0.7	0
657	Editorial: Pursuit of a Dual-Benefit Antigout Drug: A First Look at Arhalofenate. <i>Arthritis and Rheumatology</i> , 2016, 68, 1793-1796.	2.9	7
658	Adherence and persistence to urate-lowering therapies in the Irish setting. <i>Clinical Rheumatology</i> , 2016, 35, 715-721.	1.0	36
659	Barriers to Care in Gout: From Prescriber to Patient. <i>Journal of Rheumatology</i> , 2016, 43, 144-149.	1.0	53
660	Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1074-1080.	0.5	82
661	Crystal Formation in Inflammation. <i>Annual Review of Immunology</i> , 2016, 34, 173-202.	9.5	106
662	The eye and the skin in nonendocrine metabolic disorders. <i>Clinics in Dermatology</i> , 2016, 34, 166-182.	0.8	7
663	Management of gout in the real world: current practice versus guideline recommendations. <i>Postgraduate Medicine</i> , 2016, 128, 106-114.	0.9	10
664	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , 2016, 128, 34-40.	0.9	25
665	In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters. <i>Clinical Drug Investigation</i> , 2016, 36, 443-452.	1.1	23
666	Cost-effectiveness analysis of febuxostat in patients with gout in Spain. <i>Journal of Medical Economics</i> , 2016, 19, 604-610.	1.0	10
667	Dual-Energy CT in Patients with Suspected Gouty Arthritis. <i>Academic Radiology</i> , 2016, 23, 267-272.	1.3	13
668	An analytical comparison between point-of-care uric acid testing meters. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 373-382.	1.5	16
669	Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 580-586.	1.6	47
670	Allopurinol: enquête de pratique dans un centre hospitalier. <i>Pharmacien Hospitalier Et Clinicien</i> , 2016, 51, 241-244.	0.3	1
671	GOSPEL 2 Colchicine for the treatment of gout flares in France: GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. <i>Joint Bone Spine</i> , 2016, 83, 687-693.	0.8	26

#	ARTICLE	IF	CITATIONS
672	Febuxostat for the chronic management of hyperuricemia in patients with gout. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 665-673.	1.3	27
673	Gout: optimizing treatment to achieve a disease cure. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 135-144.	1.1	27
674	Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. <i>Joint Bone Spine</i> , 2016, 83, 314-317.	0.8	43
675	Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. <i>American Journal of Medicine</i> , 2016, 129, 299-306.e2.	0.6	63
677	Comorbidities in patients with gout prior to and following diagnosis: case-control study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 210-217.	0.5	171
678	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. <i>Nature Reviews Rheumatology</i> , 2016, 12, 235-242.	3.5	139
679	Genetic variation in the ABCG2 gene is associated with gout risk in the Chinese Han population. <i>Clinical Rheumatology</i> , 2016, 35, 159-163.	1.0	18
680	The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints. <i>Rheumatology International</i> , 2016, 36, 443-446.	1.5	16
681	Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. <i>Joint Bone Spine</i> , 2017, 84, 183-188.	0.8	31
682	Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. <i>Rejuvenation Research</i> , 2017, 20, 42-49.	0.9	15
683	Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: A primary care retrospective cohort study. <i>Joint Bone Spine</i> , 2017, 84, 59-64.	0.8	20
684	Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. <i>Clinical Therapeutics</i> , 2017, 39, 430-441.	1.1	34
685	Gout treatment: survey of Brazilian rheumatology residents. <i>Clinical Rheumatology</i> , 2017, 36, 1179-1188.	1.0	2
686	Achilles tendon enthesis with double contour sign revealing gout. <i>Joint Bone Spine</i> , 2017, 84, 641-642.	0.8	2
687	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.5	38
688	Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. <i>Journal of Rheumatology</i> , 2017, 44, 388-396.	1.0	111
689	Folic acid therapy reduces serum uric acid in hypertensive patients: a substudy of the China Stroke Primary Prevention Trial (CSPPT). <i>American Journal of Clinical Nutrition</i> , 2017, 105, 882-889.	2.2	43
690	Gout – a guide for the general and acute physicians. <i>Clinical Medicine</i> , 2017, 17, 54-59.	0.8	69

#	ARTICLE	IF	CITATIONS
691	Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 377-387.	0.8	15
692	A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 990-995.	0.9	3
693	Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives. <i>Arthritis Care and Research</i> , 2017, 69, 1724-1732.	1.5	15
694	Gout and Heart Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 443-460.	0.1	0
695	Chasing crystals out of the body: will treat to serum urate target for gout help us get there?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 629-631.	0.5	5
696	Consensus-based recommendations for the management of juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 329-340.	0.5	185
697	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 632-638.	0.5	118
698	Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 688-693.	0.5	55
699	Use of febuxostat in the management of gout in the United Kingdom. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 55-64.	1.2	16
700	Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population. <i>Rheumatology International</i> , 2017, 37, 571-578.	1.5	12
701	Causative Drugs of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Israel. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 823-829.	1.0	7
702	Discovery and Assessment of Atropisomers of (±)-Lesinurad. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 299-303.	1.3	44
703	Critical revision of the medical treatment of gout in Brazil. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 346-355.	0.7	4
704	GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century—A comparison with 2006 EULAR Recommendations. <i>Joint Bone Spine</i> , 2017, 84, 447-453.	0.8	21
705	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1637-1641.	0.5	75
706	Management of Gout and Hyperuricemia in CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 422-439.	2.1	119
707	A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease. <i>Joint Bone Spine</i> , 2017, 84, 709-713.	0.8	6
708	Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. <i>Liver International</i> , 2017, 37, 906-918.	1.9	44

#	ARTICLE	IF	CITATIONS
709	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1788-1796.	0.5	139
710	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1073-1085.	1.7	9
711	Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. <i>Pharmacogenomics</i> , 2017, 18, 881-890.	0.6	15
712	Gout: An old disease in new perspective – A review. <i>Journal of Advanced Research</i> , 2017, 8, 495-511.	4.4	329
714	The British Society for Rheumatology Guideline for the Management of Gout. <i>Rheumatology</i> , 2017, 56, e1-e20.	0.9	188
715	The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study. <i>Rheumatology International</i> , 2017, 37, 1187-1194.	1.5	16
716	Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e2-e2.	0.5	7
718	The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. <i>Pain and Therapy</i> , 2017, 6, 1-16.	1.5	36
719	Prevalence of calcified carotid artery atheromas on panoramic images of older men with gout: a descriptive retrospective study. <i>Dentomaxillofacial Radiology</i> , 2017, 46, 20160406.	1.3	5
720	Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 95.	0.8	18
721	Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. <i>Arthritis and Rheumatology</i> , 2017, 69, 479-482.	2.9	15
722	The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. <i>Journal of Rheumatology</i> , 2017, 44, 374-379.	1.0	31
723	Allopurinol: insights from studies of dose-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 449-462.	1.5	21
724	2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42.	0.5	1,096
725	Amputation of the first metatarsophalangeal joint due to a giant gouty tophi. <i>Medicine (United Tj ETQqO 0 0 rgBT /Overlock_10 Tf 50 1</i>	0.4	5
726	Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort. <i>Rheumatology and Therapy</i> , 2017, 4, 419-425.	1.1	7
727	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. <i>Rheumatology</i> , 2017, 56, 1729-1739.	0.9	49
728	Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 871-875.	1.0	17

#	ARTICLE	IF	CITATIONS
729	Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 317-323.	0.5	8
730	Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1057-1071.	0.9	31
731	The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 66.	2.1	8
732	Elevated UMOD methylation level in peripheral blood is associated with gout risk. <i>Scientific Reports</i> , 2017, 7, 11196.	1.6	20
733	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1965-1973.	0.5	105
734	Febuxostat-induced agranulocytosis in an end-stage renal disease patient. <i>Medicine (United States)</i> , 2017, 96, e5863.	0.4	3
735	GOSPEL 2 "À la colchicine dans le traitement de la crise de goutte en France" analyse d'un sous-groupe de l'étude GOSPEL. Doses utilisées en pratique courante sans considération de l'insuffisance rénale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 526-533.		0
736	Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients. <i>Rheumatology International</i> , 2017, 37, 1435-1440.	1.5	14
737	The Economic Value of Genetic Testing for Tolerance of Allopurinol in Gout. <i>Journal of Rheumatology</i> , 2017, 44, 717-719.	1.0	0
738	Adherence to gout management recommendations of Chinese patients. <i>Medicine (United States)</i> , 2017, 96, e8532.	0.4	18
739	Gout in primary care: Can we improve patient outcomes?. <i>BMJ Quality Improvement Reports</i> , 2017, 6, u210130.w4918.	0.8	4
740	Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements. <i>BMJ Open</i> , 2017, 7, e014928.	0.8	20
741	An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study. <i>Journal of International Medical Research</i> , 2017, 45, 1417-1429.	0.4	20
743	Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. <i>Annals of Internal Medicine</i> , 2017, 166, 52.	2.0	46
744	Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. <i>Clinical Rheumatology</i> , 2017, 36, 641-647.	1.0	41
745	Results of an Observational Cohort Study of Hyperuricemia as a Predictor of Poor Physical Performance in the Elderly. <i>Arthritis Care and Research</i> , 2017, 69, 1238-1244.	1.5	15
746	Anakinra in resistant gout: a case report. <i>Acta Clinica Belgica</i> , 2017, 72, 293-295.	0.5	7
747	Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. <i>Clinical Pharmacokinetics</i> , 2017, 56, 459-475.	1.6	34

#	ARTICLE	IF	CITATIONS
748	Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertension Research, 2017, 40, 259-263.	1.5	26
749	The relationship between serum uric acid and metabolic syndrome in premenopausal and postmenopausal women in the Jinchang Cohort. Gynecological Endocrinology, 2017, 33, 141-144.	0.7	17
750	Lesinurad Combined With Allopurinol: A Randomized, Double-blind, Placebo-controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-based Study). Arthritis and Rheumatology, 2017, 69, 203-212.	2.9	154
751	Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Current Medical Research and Opinion, 2017, 33, 117-124.	0.9	18
752	Adequacy of Online Patient Information Resources on Gout and Potentially Curative Urate-Lowering Treatment. Arthritis Care and Research, 2017, 69, 748-752.	1.5	15
753	Lesinurad: what the nephrologist should know. CKJ: Clinical Kidney Journal, 2017, 10, 679-687.	1.4	28
754	Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. Biological and Pharmaceutical Bulletin, 2017, 40, 681-686.	0.6	4
755	Factors Influencing Allopurinol Initiation in Primary Care. Annals of Family Medicine, 2017, 15, 557-560.	0.9	8
756	Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims. Journal of Pain Research, 2017, Volume 10, 327-339.	0.8	6
757	Clinical Features and Treatment of Gout. , 2017, , 1620-1644.e4.		3
758	Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 159-165.	0.8	6
759	Treatment Options for Gout. Deutsches Arzteblatt International, 2017, 114, 215-222.	0.6	43
760	Arthrose und Arthritis. , 2017, , 115-147.		0
761	DNA hypomethylation of a transcription factor binding site within the promoter of a gout risk gene NRBP1 upregulates its expression by inhibition of TFAP2A binding. Clinical Epigenetics, 2017, 9, 99.	1.8	19
762	Can't bend it and it hurts like mad? direct observation of gout consultations in routine primary health care. BMC Family Practice, 2017, 18, 91.	2.9	6
763	Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 677-683.	0.5	7
764	Urate-Lowering Therapy. , 2017, , 1061-1074.e3.		2
765	Mobile App to Streamline the Development of Wearable Sensor-Based Exercise Biofeedback Systems: System Development and Evaluation. JMIR Rehabilitation and Assistive Technologies, 2017, 4, e9.	1.1	14

#	ARTICLE	IF	CITATIONS
766	Uric acid and allopurinol aggravate absence epileptic activity in Wistar Albino Glaxo Rijswijk rats. <i>Brain Research</i> , 2018, 1686, 1-9.	1.1	4
768	Allopurinol Dose Escalation and Mortality Among Patients With Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 1298-1307.	2.9	26
769	Gout of hand and wrist: the value of US as compared with DECT. <i>European Radiology</i> , 2018, 28, 4174-4181.	2.3	34
770	Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e017542.	0.8	51
771	Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. <i>Arthritis Care and Research</i> , 2018, 70, 659-671.	1.5	19
772	Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. <i>Rheumatology</i> , 2018, 57, 826-830.	0.9	27
773	Treatment of Hyperuricemia in Chronic Kidney Disease. <i>Contributions To Nephrology</i> , 2018, 192, 135-146.	1.1	27
774	Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis. <i>Clinical Rheumatology</i> , 2018, 37, 1879-1884.	1.0	18
775	Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 772-787.	0.9	95
776	Treat to target in gout. <i>Rheumatology</i> , 2018, 57, i20-i26.	0.9	23
777	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213131.	0.5	119
778	Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. <i>Contemporary Clinical Trials</i> , 2018, 68, 102-108.	0.8	14
779	Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. <i>Scientific Reports</i> , 2018, 8, 4314.	1.6	121
780	Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. <i>Pharmacoeconomics</i> , 2018, 36, 625-636.	1.7	7
781	GOSPEL 3: prise en charge de la goutte par les médecins généralistes et rhumatologues libéraux en France au début du XXI <sup>e</sup> siècle. Comparaison aux recommandations EULAR 2006. <i>Revue Du Rhumatisme (Edition Française)</i> , 2018, 85, 165-172.	0.0	0
782	Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. <i>Joint Bone Spine</i> , 2018, 85, 311-315.	0.8	23
783	First validation of the gout activity score against gout impact scale in a primary care based gout cohort. <i>Joint Bone Spine</i> , 2018, 85, 323-325.	0.8	12
784	A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 517-522.	0.9	2



#	ARTICLE	IF	CITATIONS
785	Low-Purine Diet Is More Effective Than Normal-Purine Diet in Reducing the Risk of Gouty Attacks After Sleeve Gastrectomy in Patients Suffering of Gout Before Surgery: a Retrospective Study. <i>Obesity Surgery</i> , 2018, 28, 1263-1270.	1.1	15
786	Rehabilitation of Older Patients with Rheumatic Diseases. <i>Practical Issues in Geriatrics</i> , 2018, , 225-236.	0.3	0
788	Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 194-197.	0.6	6
789	Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. <i>Rheumatology and Therapy</i> , 2018, 5, 243-253.	1.1	25
790	Cost-effectiveness analysis of HLA-B*58. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 56-67.	0.7	31
791	In vitro toxicity assessment of nanocrystals in tissue-type cells and macrophage cells. <i>Journal of Applied Toxicology</i> , 2018, 38, 656-664.	1.4	5
792	Corticosteroid or Nonsteroidal Antiinflammatory Drugs for the Treatment of Acute Gout: A Systematic Review of Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2018, 45, 128-136.	1.0	19
793	La réponse rénale aux variations de l'uricémie est différente chez les patients goutteux comparativement aux sujets sains. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 79-84.	0.0	0
794	Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout. <i>Clinical Rheumatology</i> , 2018, 37, 773-777.	1.0	36
795	Arctium minus crude extract presents antinociceptive effect in a mice acute gout attack model. <i>Inflammopharmacology</i> , 2018, 26, 505-519.	1.9	12
796	Raman Spectroscopy as an Assay to Disentangle Zinc Oxide Carbon Nanotube Composites for Optimized Uric Acid Detection. <i>Chemosensors</i> , 2018, 6, 65.	1.8	11
797	Should our approach to diuretic using in patients with gout change?. <i>Arthritis Research and Therapy</i> , 2018, 20, 241.	1.6	1
798	Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 108.	1.6	29
799	Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. <i>Current Rheumatology Reports</i> , 2018, 20, 47.	2.1	5
800	Goals of gout treatment: a patient perspective. <i>Clinical Rheumatology</i> , 2018, 37, 2557-2566.	1.0	8
801	Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. <i>Arthritis Research and Therapy</i> , 2018, 20, 136.	1.6	60
802	Metabolomics approach by 1H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. <i>Arthritis Research and Therapy</i> , 2018, 20, 111.	1.6	53
803	The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1164-1170.	1.0	14

#	ARTICLE	IF	CITATIONS
804	Development of minimum standards of care for juvenile localized scleroderma. <i>European Journal of Pediatrics</i> , 2018, 177, 961-977.	1.3	45
805	Diagnosis and Treatment of Gout and Pseudogout for Everyday Practice. <i>Primary Care - Clinics in Office Practice</i> , 2018, 45, 213-236.	0.7	25
806	Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. <i>Journal of Pain Research</i> , 2018, Volume 11, 301-311.	0.8	11
808	Benzbromarone in the treatment of gout. <i>Advances in Rheumatology</i> , 2019, 59, 37.	0.8	70
810	Risk factors for the formation of double-contour sign and tophi in gout. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 239.	0.9	10
811	The Role of a "Treat-to-Target" Approach in the Long-Term Renal Outcomes of Patients with Gout. <i>Journal of Clinical Medicine</i> , 2019, 8, 1067.	1.0	1
812	Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. <i>BMJ Open</i> , 2019, 9, e026677.	0.8	90
813	Rôle d'un programme infirmier sur l'engagement des patients à l'égard des traitements hypo-uricémifiants: Étude qualitative d'un essai comparatif randomisé de soins infirmiers. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 622-627.	0.0	0
814	The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice. <i>PLoS ONE</i> , 2019, 14, e0221504.	1.1	8
815	Incident gout and chronic Kidney Disease: healthcare utilization and survival. <i>BMC Rheumatology</i> , 2019, 3, 11.	0.6	9
816	Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. <i>Clinical Rheumatology</i> , 2019, 38, 3521-3528.	1.0	6
817	Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus. <i>Advances in Therapy</i> , 2019, 36, 2618-2637.	1.3	53
818	Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. <i>CardioRenal Medicine</i> , 2019, 9, 344-353.	0.7	10
819	Serum/Synovial Fluid Urate Ratio as an Indicator for Distinguishing Gouty Arthritis From Other Arthritides. <i>Archives of Rheumatology</i> , 2019, 34, 220-224.	0.3	2
820	Foot structure, pain and functional ability in people with gout in primary care: cross-sectional findings from the Clinical Assessment Study of the Foot. <i>Journal of Foot and Ankle Research</i> , 2019, 12, 8.	0.7	5
821	In vivo anti-hyperuricemic activity of sesquiterpene lactones from <i>Lychnophora</i> species. <i>Revista Brasileira De Farmacognosia</i> , 2019, 29, 241-245.	0.6	11
822	Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. <i>Clinical Cardiology</i> , 2019, 42, 720-727.	0.7	12
823	Pharmacological basis for use of madecassoside in gouty arthritis: anti-inflammatory, anti-hyperuricemic, and NLRP3 inhibition. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 277-284.	1.1	18

#	ARTICLE	IF	CITATIONS
824	High serum uric acid level is associated with greater handgrip strength in the aged population. <i>Arthritis Research and Therapy</i> , 2019, 21, 73.	1.6	26
826	Economic Impact of Adherence to Pain Treatment Guidelines in Chronic Pain Patients. <i>Pain Medicine</i> , 2019, 20, 1907-1918.	0.9	8
827	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 1607-1616.	0.9	165
828	A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1113, 77-83.	1.2	7
829	Consensus-based recommendations for the management of juvenile localised scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1019-1024.	0.5	76
830	Safety and tolerability of available urate-lowering drugs: a critical review. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 261-271.	1.0	117
831	Insulin resistance is an independent predictor of erectile dysfunction in patients with gout. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 202-209.	0.7	6
832	Gout Activity Score has predictive validity and is sensitive to change: results from the Nottingham Gout Treatment Trial (Phase II). <i>Rheumatology</i> , 2019, 58, 1378-1382.	0.9	7
833	Gout. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 583-591.	0.8	18
834	Acute monoarthritis. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2019, 32, 25-31.	0.1	0
835	Non-pharmacologic measures for gout management in the prospective GOSPEL cohort: Physicians' practice and patients' compliance profiles. <i>Joint Bone Spine</i> , 2019, 86, 225-231.	0.8	2
836	Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. <i>Rheumatology</i> , 2019, 58, 836-839.	0.9	30
837	Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care. <i>Joint Bone Spine</i> , 2019, 86, 357-362.	0.8	18
838	Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor- $\kappa$ B signaling. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6718-6728.	1.2	41
839	Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. <i>Modern Rheumatology</i> , 2019, 29, 1042-1052.	0.9	30
840	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 656-671.	0.9	77
841	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 672-682.	0.9	103
842	Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. <i>American Journal of Medicine</i> , 2019, 132, 354-361.	0.6	49

#	ARTICLE	IF	CITATIONS
843	The economic burden of uncontrolled gout: how controlling gout reduces cost. <i>Journal of Medical Economics</i> , 2019, 22, 1-6.	1.0	19
844	Treatment Guidelines. , 2019, , 141-153.		1
845	Treat to Target. , 2019, , 179-183.		0
846	Reply to the comment of Mourgues et al., 2012. American guidelines for the management of gout as seen by general practitioners. <i>Joint Bone Spine</i> , 2019, 86, 279-280.	0.8	0
847	Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. <i>Rheumatology</i> , 2019, 58, 410-417.	0.9	30
848	Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 179-187.	0.8	15
849	Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 132-139.	1.0	14
850	El mÃ©todo Delphi en la investigaci3n en reumatologÃa: Â¿lo estamos haciendo bien?. <i>Revista Colombiana De ReumatologÃa</i> , 2020, 27, 177-189.	0.0	5
851	Effects of Conventional Uric Acidâ€“Lowering Therapy on Monosodium Urate Crystal Deposits. <i>Arthritis and Rheumatology</i> , 2020, 72, 150-156.	2.9	33
852	Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 449-460.	1.0	11
853	The effect of different styles of medical illustration on information comprehension, the perception of educational material and illness beliefs. <i>Patient Education and Counseling</i> , 2020, 103, 556-562.	1.0	28
854	Serum urate goal attainment and associated factors in Chinese gout patients. <i>Psychology, Health and Medicine</i> , 2020, 25, 931-939.	1.3	3
855	Development and Pilot Testing of MyGoutCare. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 320-326.	0.5	3
856	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 147-156.	0.5	9
857	Sex-Specific Differences in the Association of Metabolically Healthy Obesity With Hyperuricemia and a Network Perspective in Analyzing Factors Related to Hyperuricemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 573452.	1.5	12
858	Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 208-212.	0.5	0
859	Treatment of atypical gouty arthritis of the hip using total hip arthroplasty. <i>Medicine (United States)</i> , 2020, 99, e23027.	0.4	2
860	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. <i>Joint Bone Spine</i> , 2020, 87, 647-651.	0.8	16

#	ARTICLE	IF	CITATIONS
861	Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e036748.	0.8	11
862	Degree of blood pressure control and the risk of new-onset hyperuricemia in treated hypertensive patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1434-1434.	0.7	5
863	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , 2020, 72, 879-895.	2.9	302
864	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020, 72, 744-760.	1.5	420
865	Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. <i>Scientific Reports</i> , 2020, 10, 7578.	1.6	31
866	The Delphi method in rheumatology research: are we doing it right?. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2020, 27, 177-189.	0.1	2
867	Effect of hyperuricemia on functional outcomes and complications in patients with elbow stiffness after open arthrolysis combined with hinged external fixation: a retrospective study. <i>Journal of Shoulder and Elbow Surgery</i> , 2020, 29, 1387-1393.	1.2	2
868	Limited Knee-Joint Range of Motion in Patients With Tophaceous Gout Improved With Medical Treatment: A 18-Months Follow Up. <i>Frontiers in Medicine</i> , 2020, 7, 74.	1.2	5
869	Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. <i>Scientific Reports</i> , 2020, 10, 10734.	1.6	11
870	Personalized Medicine of Urate-Lowering Therapy for Gout. , 0, , .		2
871	Introductory Chapter: Gout. , 0, , .		0
872	Management of Gout in the United States: A Claims�based Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 180-187.	0.9	10
873	Management of hyperuricemia in asymptomatic patients: A critical appraisal. <i>European Journal of Internal Medicine</i> , 2020, 74, 8-17.	1.0	36
874	Etoricoxib prevents progression of osteolysis in repeated intra-articular monosodium urate-induced gouty arthritis in rats. <i>Journal of Advanced Research</i> , 2020, 24, 109-120.	4.4	6
875	The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Hypertension</i> , 2020, 38, 954-960.	0.3	12
876	High�throughput serum metabolomics analysis of gouty arthritis rat treated by total saponins of <i>Rhizoma Dioscoreae Makino</i> by UPLC�Q/TOF�MS. <i>Biomedical Chromatography</i> , 2020, 34, e4867.	0.8	4
877	Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008�2012). <i>Lipids in Health and Disease</i> , 2020, 19, 58.	1.2	46
878	Efficacy and tolerability of febuxostat in gout patients on dialysis. <i>Internal Medicine Journal</i> , 2021, 51, 348-354.	0.5	5

#	ARTICLE	IF	CITATIONS
879	The Colchicine Debacle Revisited. <i>JAMA Internal Medicine</i> , 2021, 181, 287.	2.6	3
880	Relationship between obesity and gout: An ancient Persian case report. <i>Obesity Medicine</i> , 2021, 21, 100310.	0.5	0
881	Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. <i>Rheumatology and Therapy</i> , 2021, 8, 183-197.	1.1	11
882	A crystal conundrum: a review of investigation and management of gout for the hand surgeon. <i>European Journal of Plastic Surgery</i> , 2021, 44, 1-8.	0.3	0
883	Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis. <i>Inflammopharmacology</i> , 2021, 29, 35-47.	1.9	3
884	Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. <i>Clinical Rheumatology</i> , 2021, 40, 1017-1026.	1.0	5
885	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 277-283.	1.4	1
886	Edible mushroom consumption and incident hyperuricemia: results from the TCLSIH cohort study. <i>Food and Function</i> , 2021, 12, 9178-9187.	2.1	7
887	Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. <i>Rheumatology</i> , 2021, 60, 4199-4204.	0.9	6
888	Association Between Use of Anti-gout Preparations and Dementia: Nested Case-€“Control Nationwide Population-Based Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 607808.	1.2	7
889	Lessons Learned from a Two-Round Delphi-based Scenario Study. <i>MethodsX</i> , 2021, 8, 101179.	0.7	49
890	Relationship between seaweeds consumption and hyperuricaemia in general adults: a Population-based study from the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) cohort study. <i>British Journal of Nutrition</i> , 2022, 127, 369-376.	1.2	2
891	Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. <i>Rheumatology</i> , 2021, 60, 5089-5097.	0.9	18
892	Nail is Systemic Disorders: Main Signs and Clues. <i>Dermatologic Clinics</i> , 2021, 39, 153-173.	1.0	3
893	Effectiveness and safety of Liuhe Pill for treating gout. <i>Medicine (United States)</i> , 2021, 100, e25533.	0.4	0
895	Modulation of Urate Transport by Drugs. <i>Pharmaceutics</i> , 2021, 13, 899.	2.0	10
896	Impact of urate-lowering therapy on quality of life indicators in patients with gout. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 62-68.	0.1	4
897	Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9221.	1.8	148

#	ARTICLE	IF	CITATIONS
898	Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 50-55.	0.1	2
899	Hyperuricemia in Renal patients: Treat or not to treat. <i>Archives of Clinical Nephrology</i> , 2021, , 050-056.	0.1	0
900	Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. <i>European Heart Journal</i> , 2021, 42, 4578-4588.	1.0	29
901	Dietary patterns and risk for hyperuricemia in the general population: Results from the TCLSIH cohort study. <i>Nutrition</i> , 2022, 93, 111501.	1.1	11
902	Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis. <i>Rheumatology</i> , 2021, 60, 3628-3634.	0.9	14
906	Musculoskeletal disease. , 2010, , 1053-1129.		5
907	Arthritis in the Elderly. , 2010, , 566-576.		1
908	Crystal Deposition Diseases. , 2012, , 1737-1743.		1
909	Clinical Features and Treatment of Gout. , 2013, , 1554-1575.e5.		2
910	Activation of peripheral KCNQ channels relieves gout pain. <i>Pain</i> , 2015, 156, 1025-1035.	2.0	26
911	Current and Future Therapeutic Options for the Management of Gout. <i>American Journal of Therapeutics</i> , 2010, 17, 402-417.	0.5	10
912	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. <i>Transplantation</i> , 2017, 101, S7-S105.	0.5	308
913	Is ultrasound changing the way we understand rheumatology? Including ultrasound examination in the classification criteria of polymyalgia rheumatica and gout.. <i>Medical Ultrasonography</i> , 2015, 17, 97.	0.4	10
914	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1870-1882.	0.5	98
915	Coexistent digital gouty and infective flexor tenosynovitis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213601.	0.2	2
916	Poorly controlled gout: who is doing poorly?. <i>Singapore Medical Journal</i> , 2016, 57, 412-414.	0.3	8
917	Liver failure associated with benzbromarone: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2019, 7, 1717-1725.	0.3	9
918	The Association of Dietary Intake of Purine-Rich Vegetables, Sugar-Sweetened Beverages and Dairy with Plasma Urate, in a Cross-Sectional Study. <i>PLoS ONE</i> , 2012, 7, e38123.	1.1	106

#	ARTICLE	IF	CITATIONS
919	Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS ONE, 2015, 10, e0135805.	1.1	8
920	Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. PLoS ONE, 2016, 11, e0146172.	1.1	18
921	Genetic Analysis of IL-17 Gene Polymorphisms in Gout in a Male Chinese Han Population. PLoS ONE, 2016, 11, e0148082.	1.1	5
922	USE OF REMICADEÂ® IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT: THEORETICAL RATIONALE AND ASSESSMENT OF OWN EXPERIENCE. Sovremennaya Revmatologiya, 2009, .	0.1	1
924	TT genotype of rs2941484 in the human HNF4G gene is associated with hyperuricemia in Chinese Han men. Oncotarget, 2017, 8, 26918-26926.	0.8	8
925	Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy. Oncotarget, 2017, 8, 111295-111308.	0.8	19
926	FACTORS EFFECTING THE DECOMPENSATION OF CHRONIC HEART FAILURE IN THE ELDERLY. Rational Pharmacotherapy in Cardiology, 2013, 9, 15-24.	0.3	2
927	mHealth App Patient Testing and Review of Educational Materials Designed for Self-Management of Gout Patients: Descriptive Qualitative Studies. JMIR MHealth and UHealth, 2018, 6, e182.	1.8	12
928	New Classification Criteria and Guideline for Management of Gout. Korean Journal of Medicine, 2018, 93, 344-350.	0.1	7
929	Treatment of hyperuricemia, gout and other crystalline arthritides. Reumatismo, 2012, 63, 276-83.	0.4	3
930	Prevalence of Hyperuricemia among Hospitalized Elderly Patients and Its Association with Metabolic Syndrome. Advances in Aging Research, 2014, 03, 329-337.	0.3	4
931	A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis. Open Journal of Rheumatology and Autoimmune Diseases, 2013, 03, 159-164.	0.1	2
932	Gout nodulosis: report of a rare case and brief review. Dermatology Online Journal, 2015, 21, .	0.2	7
933	An old disease with new insights: Update on diagnosis and treatment of gout. European Journal of Rheumatology, 2014, 49, 72-77.	1.3	9
934	Dual Energy CT: added value in gouty arthritis. Journal of the Belgian Society of Radiology, 2015, 96, 34.	0.2	4
935	Adrenocorticotrophic hormone: A powerful but underappreciated therapeutic tool for acute crystal induced arthritis?. World Journal of Rheumatology, 2013, 3, 6.	0.5	2
936	Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study. World Journal of Nephrology, 2017, 6, 132.	0.8	5
937	General practitionersâ€™ knowledge of gout and its management: a case study in Beijing. Primary Health Care Research and Development, 2021, 22, .	0.5	3



#	ARTICLE	IF	CITATIONS
938	Anti-gout Medications and Risk of Cardiovascular Disease: A Nested Case-Control Study. <i>Frontiers in Medicine</i> , 2021, 8, 739680.	1.2	4
940	MULTIMODALITY THERAPY FOR CHRONIC TOPHACEOUS GOUT. <i>Sovremennaya Revmatologiya</i> , 2008, .	0.1	0
941	SIGNIFICANCE OF DIET AND DIETARY SUPPLEMENTS IN GOUT. <i>Sovremennaya Revmatologiya</i> , 2008, .	0.1	0
942	Arthrose und Arthritis. , 2009, , 101-126.		0
943	Gout Treatment. , 2009, , 361-367.		0
945	Gichtmittel. , 2009, , 569-573.		0
946	How to optimize treatment in patients with gout and chronic arthritis Urisan is in focus. <i>Sovremennaya Revmatologiya</i> , 2009, .	0.1	0
947	EXPERIENCE WITH URISAN LONG USED IN GOUTY PATIENTS. <i>Sovremennaya Revmatologiya</i> , 2009, .	0.1	0
949	Jicht. , 2010, , 36-47.		0
950	Gichtmittel. , 2010, , 597-601.		0
951	M90 Arthritis. , 2010, , 1-42.		0
953	An acutely swollen knee. <i>BMJ: British Medical Journal</i> , 2010, 341, c4441-c4441.	2.4	0
954	VALUE OF THE PHYTODRUGS PROLIT AND URISAN IN THE TREATMENT OF GOUTY PATIENTS. <i>Sovremennaya Revmatologiya</i> , 2010, .	0.1	0
955	Estimation of arterial rigidity parameters in patients with gout and essential hypertension. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2010, .	0.2	4
956	Management in primary care. <i>BMJ: British Medical Journal</i> , 2011, 342, d117-d117.	2.4	0
957	NHG-Standaard Arthritis. , 2011, , 579-601.		1
958	Arthrose und Arthritis. , 2011, , 101-126.		0
959	The management of gout and hyperuricemia. , 2011, , 1867-1874.e1.		1

#	ARTICLE	IF	CITATIONS
960	Gichtmittel. , 2011, , 615-619.		0
961	Kristallarthropathien. , 2012, , 173-178.		0
962	Gichtmittel. , 2012, , 621-626.		0
963	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
965	Knobbels aan de hiel. , 2012, , 144-145.		0
966	The Prevalence and Risk Factors for Gout. , 2013, , 9-23.		0
967	The Pathognomic Radiologic Features of Gout in the Fingers and Review of the Literature, Including the Latest Drug Therapy. Open Journal of Radiology, 2013, 03, 108-111.	0.1	0
968	Voeding bij jicht en hyperuricemie. , 2013, , 1142-1156.		0
969	Kristalartritis. , 2013, , 103-113.		0
970	Purinstoffwechsel â€“ Gicht. , 2013, , 559-567.		0
971	Antihyperuricemic Agents. , 2013, , 1001-1013.		0
972	Gichtmittel. , 2013, , 609-613.		0
973	Canakinumab (an interleukin 1Î² inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologiya, 2013, Å, 428.	0.2	2
975	Gout: A clinical overview and its association with cardiovascular diseases. World Journal of Rheumatology, 2014, 4, 62.	0.5	0
976	Gelenk- und Muskelschmerzen. , 2014, , 1-34.		0
977	To treat or not to treat asymptomatic hyperuricemia. Saudi Journal of Medicine and Medical Sciences, 2014, 2, 95.	0.3	0
978	Treatment of Goutâ€™A new Approach. IOSR Journal of Dental and Medical Sciences, 2014, 13, 60-64.	0.0	1
979	The morphological changes in joints tissues in cases of primary tophus gout. Ortopediia, Trumatologiya i Protezirovaniye, 2014, .	0.0	0

#	ARTICLE	IF	CITATIONS
980	NEW INTERNATIONAL RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF GOUT. Nauchno-Prakticheskaya Revmatologiya, 2014, 52, 141.	0.2	6
981	Management of gout and hyperuricemia. , 2015, , 1575-1582.		0
982	Kristallarthropathien. , 2015, , 1-6.		0
984	Septic arthritis with concomitant gouty arthritis. Journal of Mahatma Gandhi Institute of Medical Sciences, 2015, 20, 183.	0.1	0
985	Musculoskeletal ultrasonography in gout. Medical Ultrasonography, 2015, 17, 535-40.	0.4	11
986	Gichtmittel. , 2016, , 481-484.		0
987	Gout Transitions from Medieval Times into the 21 Century. The Open Urology & Nephrology Journal, 2016, 9, 22-26.	0.2	0
989	Dietary changes in patients with diabetes mellitus in combination with gout. MÃ¼narodnij EndokrinologÃ¼nj Å½urnal, 2016, .	0.1	1
990	Hyperuricaemia and gouty arthropathy: diagnosis and treatment. Interni Medicina Pro Praxi, 2016, 18, 137-141.	0.0	1
991	Hyperuricemia is Associated with Musculo-skeletal Pain - Results from a Cross-sectional Study. Open Pain Journal, 2016, 9, 15-25.	0.4	2
992	Symptomatic treatment of gouty arthritis. Klinicka Farmakologie A Farmacie, 2016, 30, 32-37.	0.1	0
995	THE RELATIONSHIP BETWEEN CLINICAL SYMPTOMS AND ULTRASONOGRAPHIC SIGNS IN GOUT. Health Sciences, 2017, 27, 70-77.	0.0	0
996	Uric Acid-Hypertension Relationships. Updates in Hypertension and Cardiovascular Protection, 2018, , 351-382.	0.1	0
997	DIET IN GOUT AND HYPERURICEMIA. Nauchno-Prakticheskaya Revmatologiya, 2017, 55, 436-445.	0.2	3
999	Controversies in the treatment of gout. Vnitri Lekarstvi, 2018, 64, 753-761.	0.1	1
1000	The current treatment strategy for gouty arthritis. Sovremennaya Revmatologiya, 2018, 12, 70-75.	0.1	0
1001	Current strategy in the treatment of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 746-752.	0.2	6
1002	Anomalies du bilan de lâ€™acide urique. , 2019, , 197-208.		0

#	ARTICLE	IF	CITATIONS
1003	Artritis gotosa deformante. FMC Formacion Medica Continuada En Atencion Primaria, 2019, 26, 181-182.	0.0	0
1004	Current Possibilities in the Correction of Hyperuricemia in Patients with Urolithiasis and Uric Acid Hypercrystallization. Health of Man, 2019, .	0.1	0
1005	Three-component combined antihypertensive therapy in patients with arterial hypertension and abdominal obesity. Data of 9-month observation. Hypertension, 2019, .	0.2	0
1006	Use of the Gout Impact Scale to Evaluate Quality of Life in Chinese Subjects with Gout: A Cross-Sectional Study. Medical Science Monitor, 2020, 26, e925593.	0.5	5
1008	Bone mineral density and trabecular bone score, hyperuricemia and metabolic syndrome in postmenopausal women. BolĚ1, Sustavy, PozvonoĚnik, 2020, 10, 57-60.	0.1	1
1009	International position paper on febuxostat. Clinical Rheumatology, 2010, 29, 835.	1.0	3
1010	Gout in Pregnancy: A Rare Phenomenon. Cureus, 2020, 12, e11697.	0.2	0
1011	Taking the stress out of managing gout. Canadian Family Physician, 2009, 55, 1209-12.	0.1	3
1013	Role of Dual-Energy Computed Tomography in the Identification of Monosodium Urate Deposition in Gout Patients: A Comprehensive Analysis of 828 Joints According to Structural Joint Damage. Cureus, 2021, 13, e19930.	0.2	1
1014	Intra-articular glucocorticoid injection site: best practice guidelines. Meditsinskiy Sovet, 2021, , 155-162.	0.1	0
1015	Relationship between hyperuricemia with deposition and sexual dysfunction in males and females. Journal of Endocrinological Investigation, 2022, 45, 691-703.	1.8	15
1016	Recommendations for the Management of Uveitis Associated with Juvenile Idiopathic Arthritis: The Czech and Slovak Adaptation of the Share Initiative. Ceska A Slovenska Oftalmologie, 2020, 76, 182-196.	0.1	0
1017	To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis. Journal of the American Board of Family Medicine, 2022, 35, 140-151.	0.8	11
1018	The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials. Advances in Rheumatology, 2022, 62, 5.	0.8	3
1019	Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study. Frontiers in Medicine, 2021, 8, 806710.	1.2	6
1020	Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1667-1678.	1.8	3
1021	A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study. JMIR Medical Informatics, 2022, 10, e33026.	1.3	5
1023	Efficacy and Safety of Acupuncture Combined with Herbal Medicine in Treating Gouty Arthritis: Meta-Analysis of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-15.	0.5	3

#	ARTICLE	IF	CITATIONS
1024	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2021, 2021, CD010120.	1.5	7
1025	Generalized pain hypersensitivity and associated factors in gout. Rheumatology, 2022, 61, 3640-3646.	0.9	2
1026	Management of gout in the primary care setting. Malaysian Family Physician, 2022, 17, 2-9.	0.2	2
1027	Effect of Baihu and Guizhi decoction in acute gouty arthritis: study protocol for a randomized controlled trial. Trials, 2022, 23, 317.	0.7	1
1028	One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis Research and Therapy, 2022, 24, 88.	1.6	12
1029	The association between low carbohydrate diet scores and cardiometabolic risk factors in Chinese adults. British Journal of Nutrition, 2023, 129, 324-335.	1.2	0
1031	Comorbidities in gouty arthritis. Journal of Investigative Medicine, 2011, 59, 1211-20.	0.7	9
1032	Association of dietary patterns with blood uric acid concentration and hyperuricemia in northern Chinese adults. Nutrition Journal, 2022, 21, .	1.5	10
1033	The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney. Internal Medicine Journal, 2023, 53, 1450-1457.	0.5	2
1034	ÐÐµÐ·ÑfÐ»ÑCEÑ,Ð°Ñ,Ñ· Ð¿ÑCEÐ,Ð¼Ð¼Ð¼Ð¼Ð¼Ð¼Ð¼·Á«Ð°Ð°»ÑCEÐ·Ð¼Ð°Ð° Ð¼Ñ, Ð¿Ð¼Ð°Ð°Ð°ÑÑÑ·Á» Ð¿ÑCEÐ,Ð¼ÑÑ,ÑÑÑÑ... Ð¿		
1035	Mapping Knowledge Structure and Global Research Trends in Gout: A Bibliometric Analysis From 2001 to 2021. Frontiers in Public Health, 0, 10, .	1.3	16
1036	Superiority of <scp>Lowâ€Dose</scp> Benzbromarone to <scp>Lowâ€Dose</scp> Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. Arthritis and Rheumatology, 2022, 74, 2015-2023.	2.9	14
1037	Treatment Guidelines in Gout. Rheumatic Disease Clinics of North America, 2022, 48, 659-678.	0.8	3
1038	Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients, 2022, 14, 3525.	1.7	19
1039	Surgical Treatment of Hand and Foot Gout Stone and Influence Factors on Prognosis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	0.7	2
1040	Radiographic Findings of Inflammatory Arthritis and Mimics in the Hands. Diagnostics, 2022, 12, 2134.	1.3	4
1041	Association between hyperuricemia and metabolic syndrome: A cross-sectional study in Tibetan adults on the Tibetan plateau. Frontiers in Endocrinology, 0, 13, .	1.5	9
1042	A Brief Review of Natural Products with Urate Transporter 1 Inhibition for the Treatment of Hyperuricemia. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-16.	0.5	2

#	ARTICLE	IF	CITATIONS
1044	Hypertension and asymptomatic hyperuricemia: algorithm of diagnostics and management (literature) Tj ETQq0 0 0 rgBT /Ovgrlock 10 T	0.1	0
1045	Hit and miss: The accuracy of intra-articular injections of the first metatarsophalangeal joint. , 2022, 1, .		0
1046	Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients. Journal of Orthopaedic Surgery and Research, 2023, 18, .	0.9	2
1047	The Relevance of Hyperuricaemia. European Medical Journal Rheumatology, 0, , 100-104.	0.0	0
1048	Treatment of Gout. , 2023, , 519-530.		0
1049	Gender differences in illness perceptions and disease management in patients with gout, results from a questionnaire study in Western Sweden. BMC Musculoskeletal Disorders, 2023, 24, .	0.8	2
1050	Review on Diagnosis & Management of Gout in Primary Health Care. Pharmacophore, 2022, 13, 121-124.	0.2	0
1051	Using human genetics to understand the epidemiological association between obesity, serum urate, and gout. Rheumatology, 2023, 62, 3280-3290.	0.9	0
1052	Towards a more ambitious uricemia target to improve joint and cardiovascular outcomes in gout. , 0, , 20-25.		0
1053	Joint Disorders. , 2013, , 929-943.e5.		0
1054	Hyperurikemia in chronic kidney disease stage 4 â€” the issue of suitability of urate-lowering therapy. PoÅki, 2023, 12, 54-57.	0.1	0
1055	Anti-hyperuricemia effect of hesperetin is mediated by inhibiting the activity of xanthine oxidase and promoting excretion of uric acid. Frontiers in Pharmacology, 0, 14, .	1.6	1
1056	Evaluation of the effect of long-term use of glucocorticoids on the risk of developing diabetes mellitus in patients with gout. Obesity and Metabolism, 2023, 19, 378-386.	0.4	0
1059	Uric acid en route to gout. Advances in Clinical Chemistry, 2023, , 209-275.	1.8	0
1066	A Scoping Review of the Efficacy and Safety of Methotrexate Compared to Mycophenolate Mofetil in the Treatment of Juvenile Localized Scleroderma in Children and Young Adults. SN Comprehensive Clinical Medicine, 2023, 5, .	0.3	0